#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Machine Prediction
Text=The major depressive disorder GWAS-supported variant rs10514299 in TMEM161B-MEF2C predicts putamen activation during reward processing in alcohol dependence Alcohol dependence (AD) frequently co-occurs with major depressive disorder (MDD).
1-1	0-3	The	_
1-2	4-9	major	_
1-3	10-20	depressive	_
1-4	21-29	disorder	_
1-5	30-44	GWAS-supported	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-6	45-52	variant	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-7	53-63	rs10514299	_
1-8	64-66	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-9	67-81	TMEM161B-MEF2C	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-10	82-90	predicts	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-11	91-98	putamen	_
1-12	99-109	activation	_
1-13	110-116	during	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-14	117-123	reward	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-15	124-134	processing	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-16	135-137	in	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	138-145	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	146-156	dependence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-19	157-164	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-20	165-175	dependence	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-21	176-177	(	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-22	177-179	AD	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-23	179-180	)	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-24	181-191	frequently	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-25	192-201	co-occurs	_
1-26	202-206	with	_
1-27	207-212	major	_
1-28	213-223	depressive	_
1-29	224-232	disorder	_
1-30	233-234	(	_
1-31	234-237	MDD	_
1-32	237-238	)	_
1-33	238-239	.	_

Text=While this comorbidity is associated with an increase in disease burden, worse treatment outcomes, and greater economic costs, the underlying neurobiology remains poorly understood.
2-1	240-245	While	_
2-2	246-250	this	_
2-3	251-262	comorbidity	_
2-4	263-265	is	_
2-5	266-276	associated	_
2-6	277-281	with	_
2-7	282-284	an	_
2-8	285-293	increase	_
2-9	294-296	in	_
2-10	297-304	disease	_
2-11	305-311	burden	_
2-12	311-312	,	_
2-13	313-318	worse	_
2-14	319-328	treatment	_
2-15	329-337	outcomes	_
2-16	337-338	,	_
2-17	339-342	and	_
2-18	343-350	greater	_
2-19	351-359	economic	_
2-20	360-365	costs	_
2-21	365-366	,	_
2-22	367-370	the	_
2-23	371-381	underlying	_
2-24	382-394	neurobiology	_
2-25	395-402	remains	_
2-26	403-409	poorly	_
2-27	410-420	understood	_
2-28	420-421	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus

Text=A recent large-scale GWAS of MDD has identified a locus in the TMEM161B-MEF2C region (rs10514299) as a novel risk variant; however, the biological relevance of this variant has not yet been studied.
3-1	422-423	A	_
3-2	424-430	recent	_
3-3	431-442	large-scale	_
3-4	443-447	GWAS	_
3-5	448-450	of	_
3-6	451-454	MDD	_
3-7	455-458	has	_
3-8	459-469	identified	_
3-9	470-471	a	_
3-10	472-477	locus	_
3-11	478-480	in	_
3-12	481-484	the	_
3-13	485-499	TMEM161B-MEF2C	_
3-14	500-506	region	_
3-15	507-508	(	_
3-16	508-518	rs10514299	_
3-17	518-519	)	_
3-18	520-522	as	_
3-19	523-524	a	_
3-20	525-530	novel	_
3-21	531-535	risk	_
3-22	536-543	variant	_
3-23	543-544	;	_
3-24	545-552	however	_
3-25	552-553	,	_
3-26	554-557	the	_
3-27	558-568	biological	_
3-28	569-578	relevance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-29	579-581	of	_
3-30	582-586	this	_
3-31	587-594	variant	_
3-32	595-598	has	_
3-33	599-602	not	_
3-34	603-606	yet	_
3-35	607-611	been	_
3-36	612-619	studied	_
3-37	619-620	.	_

Text=Given previous reports of disrupted reward processing in both AD and MDD, we hypothesized that rs10514299 would be associated with differences in striatal BOLD responses during reward / loss anticipation in AD.
4-1	621-626	Given	_
4-2	627-635	previous	_
4-3	636-643	reports	_
4-4	644-646	of	_
4-5	647-656	disrupted	_
4-6	657-663	reward	_
4-7	664-674	processing	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
4-8	675-677	in	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
4-9	678-682	both	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
4-10	683-685	AD	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
4-11	686-689	and	_
4-12	690-693	MDD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-13	693-694	,	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-14	695-697	we	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-15	698-710	hypothesized	_
4-16	711-715	that	_
4-17	716-726	rs10514299	_
4-18	727-732	would	_
4-19	733-735	be	_
4-20	736-746	associated	_
4-21	747-751	with	_
4-22	752-763	differences	_
4-23	764-766	in	_
4-24	767-775	striatal	_
4-25	776-780	BOLD	_
4-26	781-790	responses	_
4-27	791-797	during	_
4-28	798-804	reward	_
4-29	804-805	/	_
4-30	805-809	loss	_
4-31	810-822	anticipation	_
4-32	823-825	in	_
4-33	826-828	AD	_
4-34	828-829	.	_

Text=DNA samples from 45 recently detoxified patients with AD and 45 healthy controls (HC) were genotyped for rs10514299.
5-1	830-833	DNA	_
5-2	834-841	samples	_
5-3	842-846	from	_
5-4	847-849	45	_
5-5	850-858	recently	_
5-6	859-869	detoxified	_
5-7	870-878	patients	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-8	879-883	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-9	884-886	AD	_
5-10	887-890	and	_
5-11	891-893	45	_
5-12	894-901	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-13	902-910	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-14	911-912	(	_
5-15	912-914	HC	_
5-16	914-915	)	_
5-17	916-920	were	_
5-18	921-930	genotyped	_
5-19	931-934	for	_
5-20	935-945	rs10514299	_
5-21	945-946	.	_

Text=Participants performed the Monetary Incentive Delay task in a 3 - Tesla MRI scanner.
6-1	947-959	Participants	_
6-2	960-969	performed	_
6-3	970-973	the	_
6-4	974-982	Monetary	_
6-5	983-992	Incentive	_
6-6	993-998	Delay	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-7	999-1003	task	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-8	1004-1006	in	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-9	1007-1008	a	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-10	1009-1010	3	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-11	1010-1011	-	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-12	1011-1016	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-13	1017-1020	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-14	1021-1028	scanner	_
6-15	1028-1029	.	_

Text=Effects of rs10514299 on striatal activation during anticipation of high / low reward / loss were investigated.
7-1	1030-1037	Effects	_
7-2	1038-1040	of	_
7-3	1041-1051	rs10514299	_
7-4	1052-1054	on	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-5	1055-1063	striatal	_
7-6	1064-1074	activation	_
7-7	1075-1081	during	_
7-8	1082-1094	anticipation	_
7-9	1095-1097	of	_
7-10	1098-1102	high	_
7-11	1102-1103	/	_
7-12	1103-1106	low	_
7-13	1107-1113	reward	_
7-14	1113-1114	/	_
7-15	1114-1118	loss	_
7-16	1119-1123	were	_
7-17	1124-1136	investigated	_
7-18	1136-1137	.	_

Text=Furthermore, we examined associations between rs10514299 and lifetime AD diagnosis in two independent clinical samples [NIAAA: n = 1858 (1123 cases, 735 controls); SAGE: n = 3838 (1848 cases, 1990 controls)], as well as its association with depression severity in a subsample of individuals with a lifetime AD diagnosis (n = 953).
8-1	1138-1149	Furthermore	_
8-2	1149-1150	,	_
8-3	1151-1153	we	_
8-4	1154-1162	examined	_
8-5	1163-1175	associations	_
8-6	1176-1183	between	_
8-7	1184-1194	rs10514299	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
8-8	1195-1198	and	_
8-9	1199-1207	lifetime	_
8-10	1208-1210	AD	_
8-11	1211-1220	diagnosis	_
8-12	1221-1223	in	_
8-13	1224-1227	two	_
8-14	1228-1239	independent	_
8-15	1240-1248	clinical	_
8-16	1249-1256	samples	_
8-17	1257-1258	[	_
8-18	1258-1263	NIAAA	_
8-19	1263-1264	:	_
8-20	1265-1266	n	_
8-21	1267-1268	=	_
8-22	1269-1273	1858	_
8-23	1274-1275	(	_
8-24	1275-1279	1123	_
8-25	1280-1285	cases	_
8-26	1285-1286	,	_
8-27	1287-1290	735	_
8-28	1291-1299	controls	_
8-29	1299-1300	)	_
8-30	1300-1301	;	_
8-31	1302-1306	SAGE	_
8-32	1306-1307	:	_
8-33	1308-1309	n	_
8-34	1310-1311	=	_
8-35	1312-1316	3838	_
8-36	1317-1318	(	_
8-37	1318-1322	1848	_
8-38	1323-1328	cases	_
8-39	1328-1329	,	_
8-40	1330-1334	1990	_
8-41	1335-1343	controls	_
8-42	1343-1344	)	_
8-43	1344-1345	]	_
8-44	1345-1346	,	_
8-45	1347-1349	as	_
8-46	1350-1354	well	_
8-47	1355-1357	as	_
8-48	1358-1361	its	_
8-49	1362-1373	association	_
8-50	1374-1378	with	_
8-51	1379-1389	depression	_
8-52	1390-1398	severity	_
8-53	1399-1401	in	_
8-54	1402-1403	a	_
8-55	1404-1413	subsample	_
8-56	1414-1416	of	_
8-57	1417-1428	individuals	_
8-58	1429-1433	with	_
8-59	1434-1435	a	_
8-60	1436-1444	lifetime	_
8-61	1445-1447	AD	_
8-62	1448-1457	diagnosis	_
8-63	1458-1459	(	_
8-64	1459-1460	n	_
8-65	1461-1462	=	_
8-66	1463-1466	953	_
8-67	1466-1467	)	_
8-68	1467-1468	.	_

Text=Patients carrying the T allele showed significantly greater putamen activation during anticipation of high reward (p = 0.014), low reward (at trend-level; p = 0.081), high loss (p = 0.024), and low loss (p = 0.046) compared to HCs.
9-1	1469-1477	Patients	_
9-2	1478-1486	carrying	_
9-3	1487-1490	the	_
9-4	1491-1492	T	_
9-5	1493-1499	allele	_
9-6	1500-1506	showed	_
9-7	1507-1520	significantly	_
9-8	1521-1528	greater	_
9-9	1529-1536	putamen	_
9-10	1537-1547	activation	_
9-11	1548-1554	during	_
9-12	1555-1567	anticipation	_
9-13	1568-1570	of	_
9-14	1571-1575	high	_
9-15	1576-1582	reward	_
9-16	1583-1584	(	_
9-17	1584-1585	p	_
9-18	1586-1587	=	_
9-19	1588-1593	0.014	_
9-20	1593-1594	)	_
9-21	1594-1595	,	_
9-22	1596-1599	low	_
9-23	1600-1606	reward	_
9-24	1607-1608	(	_
9-25	1608-1610	at	_
9-26	1611-1622	trend-level	_
9-27	1622-1623	;	_
9-28	1624-1625	p	_
9-29	1626-1627	=	_
9-30	1628-1633	0.081	_
9-31	1633-1634	)	_
9-32	1634-1635	,	_
9-33	1636-1640	high	_
9-34	1641-1645	loss	_
9-35	1646-1647	(	_
9-36	1647-1648	p	_
9-37	1649-1650	=	_
9-38	1651-1656	0.024	_
9-39	1656-1657	)	_
9-40	1657-1658	,	_
9-41	1659-1662	and	_
9-42	1663-1666	low	_
9-43	1667-1671	loss	_
9-44	1672-1673	(	_
9-45	1673-1674	p	_
9-46	1675-1676	=	_
9-47	1677-1682	0.046	_
9-48	1682-1683	)	_
9-49	1684-1692	compared	_
9-50	1693-1695	to	_
9-51	1696-1699	HCs	_
9-52	1699-1700	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus

Text=Association analyses in the NIAAA sample showed a trend-level relationship between rs10514299 and a lifetime AD diagnosis in the European American subgroup (odds ratio = 0.82, p = 0.09).
10-1	1701-1712	Association	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
10-2	1713-1721	analyses	_
10-3	1722-1724	in	_
10-4	1725-1728	the	_
10-5	1729-1734	NIAAA	_
10-6	1735-1741	sample	_
10-7	1742-1748	showed	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
10-8	1749-1750	a	_
10-9	1751-1762	trend-level	_
10-10	1763-1775	relationship	_
10-11	1776-1783	between	_
10-12	1784-1794	rs10514299	_
10-13	1795-1798	and	_
10-14	1799-1800	a	_
10-15	1801-1809	lifetime	_
10-16	1810-1812	AD	_
10-17	1813-1822	diagnosis	_
10-18	1823-1825	in	_
10-19	1826-1829	the	_
10-20	1830-1838	European	_
10-21	1839-1847	American	_
10-22	1848-1856	subgroup	_
10-23	1857-1858	(	_
10-24	1858-1862	odds	_
10-25	1863-1868	ratio	_
10-26	1869-1870	=	_
10-27	1871-1875	0.82	_
10-28	1875-1876	,	_
10-29	1877-1878	p	_
10-30	1879-1880	=	_
10-31	1881-1885	0.09	_
10-32	1885-1886	)	_
10-33	1886-1887	.	_

Text=This finding was not replicated in the SAGE sample.
11-1	1888-1892	This	_
11-2	1893-1900	finding	_
11-3	1901-1904	was	_
11-4	1905-1908	not	_
11-5	1909-1919	replicated	_
11-6	1920-1922	in	_
11-7	1923-1926	the	_
11-8	1927-1931	SAGE	_
11-9	1932-1938	sample	_
11-10	1938-1939	.	_

Text=In the NIAAA sample, the T allele was significantly associated with greater depression symptom severity in individuals with a lifetime AD diagnosis (β = 1.25, p = 0.02); this association was driven by the African American ancestry subgroup (β = 2.11, p = 0.008).
12-1	1940-1942	In	_
12-2	1943-1946	the	_
12-3	1947-1952	NIAAA	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-4	1953-1959	sample	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-5	1959-1960	,	_
12-6	1961-1964	the	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-7	1965-1966	T	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-8	1967-1973	allele	_
12-9	1974-1977	was	_
12-10	1978-1991	significantly	_
12-11	1992-2002	associated	_
12-12	2003-2007	with	_
12-13	2008-2015	greater	_
12-14	2016-2026	depression	_
12-15	2027-2034	symptom	_
12-16	2035-2043	severity	_
12-17	2044-2046	in	_
12-18	2047-2058	individuals	_
12-19	2059-2063	with	_
12-20	2064-2065	a	_
12-21	2066-2074	lifetime	_
12-22	2075-2077	AD	_
12-23	2078-2087	diagnosis	_
12-24	2088-2089	(	_
12-25	2089-2090	β	_
12-26	2091-2092	=	_
12-27	2093-2097	1.25	_
12-28	2097-2098	,	_
12-29	2099-2100	p	_
12-30	2101-2102	=	_
12-31	2103-2107	0.02	_
12-32	2107-2108	)	_
12-33	2108-2109	;	_
12-34	2110-2114	this	_
12-35	2115-2126	association	_
12-36	2127-2130	was	_
12-37	2131-2137	driven	_
12-38	2138-2140	by	_
12-39	2141-2144	the	_
12-40	2145-2152	African	_
12-41	2153-2161	American	_
12-42	2162-2170	ancestry	_
12-43	2171-2179	subgroup	_
12-44	2180-2181	(	_
12-45	2181-2182	β	_
12-46	2183-2184	=	_
12-47	2185-2189	2.11	_
12-48	2189-2190	,	_
12-49	2191-2192	p	_
12-50	2193-2194	=	_
12-51	2195-2200	0.008	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-52	2200-2201	)	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-53	2201-2202	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

Text=We show for the first time that the previously identified MDD risk variant rs10514299 in TMEM161B-MEF2C predicts neuronal correlates of reward processing in an AD phenotype, possibly explaining part of the shared pathophysiology and comorbidity between the disorders.
13-1	2203-2205	We	_
13-2	2206-2210	show	_
13-3	2211-2214	for	_
13-4	2215-2218	the	_
13-5	2219-2224	first	_
13-6	2225-2229	time	_
13-7	2230-2234	that	_
13-8	2235-2238	the	_
13-9	2239-2249	previously	_
13-10	2250-2260	identified	_
13-11	2261-2264	MDD	_
13-12	2265-2269	risk	_
13-13	2270-2277	variant	_
13-14	2278-2288	rs10514299	_
13-15	2289-2291	in	_
13-16	2292-2306	TMEM161B-MEF2C	_
13-17	2307-2315	predicts	_
13-18	2316-2324	neuronal	_
13-19	2325-2335	correlates	_
13-20	2336-2338	of	_
13-21	2339-2345	reward	_
13-22	2346-2356	processing	_
13-23	2357-2359	in	_
13-24	2360-2362	an	_
13-25	2363-2365	AD	_
13-26	2366-2375	phenotype	_
13-27	2375-2376	,	_
13-28	2377-2385	possibly	_
13-29	2386-2396	explaining	_
13-30	2397-2401	part	_
13-31	2402-2404	of	_
13-32	2405-2408	the	_
13-33	2409-2415	shared	_
13-34	2416-2431	pathophysiology	_
13-35	2432-2435	and	_
13-36	2436-2447	comorbidity	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-37	2448-2455	between	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-38	2456-2459	the	_
13-39	2460-2469	disorders	_
13-40	2469-2470	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=Materials and methods Participants Demographics and characteristics of the Neuroimaging Sample Alcohol dependence N = 45 Healthy controls N = 45 p value Gender 0.004 Male 35 (77.8) 22 (48.9) Female 10 (22.2) 23 (51.1) Age, mean years (SD) 43.25 (10.73) 36.30 (10.94) 0.003 Ethnicity 0.088 Black / African American 24 (53.3) 18 (40.0) European American 17 (37.8) 16 (35.6) Asian 0 (0.0) 6 (13.3) Multiracial 1 (2.2) 3 (6.7) Unknown 3 (6.7) 2 (4.4) Smokers 26 (57.8) 0 (0.0) <0.0001 Rs10514299 Genotype CC 35 33 0.624 CT / TT 10 12 Alcohol dependence severity score, mean (SD) 19.68 (7.70) (N = 38) 1.13 (2.25) (N = 31) <0.0001 Average number of drinking days in past 90 days, mean (SD) 69.60 (25.19) 18.76 (16.08) <0.0001 Number of heavy drinking days in past 90 days, mean (SD) 59.49 (30.65) 2.42 (7.19) <0.0001 Average number of drinks per drinking day, mean (SD) 13.11 (8.84) 1.80 (1.78) <0.0001 MADRS Score, mean (SD) 12.13 (10.21) 0.87 (1.67) <0.0001 Any anxiety disorder—current 8 (9.0) 1 (1.1) 0.010 Any anxiety disorder—lifetime 11 (12.4) 1 (1.1) 0.002 Generalized anxiety disorder—current 3 (3.4) 1 (1.1) 0.030 Generalized anxiety disorder—lifetime 3 (3.4) 1 (1.1) 0.030 Posttraumatic stress disorder—current 2 (2.3) 0 (0.0) 0.150 Posttraumatic stress disorder—lifetime 2 (2.3) 0 (0.0) 0.150 Any mood disorder—current 5 (5.6) 0 (0.0) 0.020 Any mood disorder—lifetime 10 (11.2) 8 (9.0) 0.560 Major depressive disorder—current 3 (3.4) 0 (0.0) 0.070 Major depressive disorder—lifetime 9 (10.1) 8 (9.0) 0.750 Note.
38-1	7678-7687	Materials	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
38-2	7688-7691	and	_
38-3	7692-7699	methods	_
38-4	7700-7712	Participants	_
38-5	7713-7725	Demographics	_
38-6	7726-7729	and	_
38-7	7730-7745	characteristics	_
38-8	7746-7748	of	_
38-9	7749-7752	the	_
38-10	7753-7765	Neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
38-11	7766-7772	Sample	_
38-12	7774-7781	Alcohol	_
38-13	7782-7792	dependence	_
38-14	7793-7794	N	_
38-15	7795-7796	=	_
38-16	7797-7799	45	_
38-17	7800-7807	Healthy	_
38-18	7808-7816	controls	_
38-19	7817-7818	N	_
38-20	7819-7820	=	_
38-21	7821-7823	45	_
38-22	7824-7825	p	_
38-23	7826-7831	value	_
38-24	7834-7840	Gender	_
38-25	7843-7848	0.004	_
38-26	7852-7856	Male	_
38-27	7857-7859	35	_
38-28	7860-7861	(	_
38-29	7861-7865	77.8	_
38-30	7865-7866	)	_
38-31	7867-7869	22	_
38-32	7870-7871	(	_
38-33	7871-7875	48.9	_
38-34	7875-7876	)	_
38-35	7881-7887	Female	_
38-36	7888-7890	10	_
38-37	7891-7892	(	_
38-38	7892-7896	22.2	_
38-39	7896-7897	)	_
38-40	7898-7900	23	_
38-41	7901-7902	(	_
38-42	7902-7906	51.1	_
38-43	7906-7907	)	_
38-44	7911-7914	Age	_
38-45	7914-7915	,	_
38-46	7916-7920	mean	_
38-47	7921-7926	years	_
38-48	7927-7928	(	_
38-49	7928-7930	SD	_
38-50	7930-7931	)	_
38-51	7932-7937	43.25	_
38-52	7938-7939	(	_
38-53	7939-7944	10.73	_
38-54	7944-7945	)	_
38-55	7946-7951	36.30	_
38-56	7952-7953	(	_
38-57	7953-7958	10.94	_
38-58	7958-7959	)	_
38-59	7960-7965	0.003	_
38-60	7968-7977	Ethnicity	_
38-61	7980-7985	0.088	_
38-62	7989-7994	Black	_
38-63	7994-7995	/	_
38-64	7995-8002	African	_
38-65	8003-8011	American	_
38-66	8012-8014	24	_
38-67	8015-8016	(	_
38-68	8016-8020	53.3	_
38-69	8020-8021	)	_
38-70	8022-8024	18	_
38-71	8025-8026	(	_
38-72	8026-8030	40.0	_
38-73	8030-8031	)	_
38-74	8036-8044	European	_
38-75	8045-8053	American	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-76	8054-8056	17	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-77	8057-8058	(	_
38-78	8058-8062	37.8	_
38-79	8062-8063	)	_
38-80	8064-8066	16	_
38-81	8067-8068	(	_
38-82	8068-8072	35.6	_
38-83	8072-8073	)	_
38-84	8078-8083	Asian	_
38-85	8084-8085	0	_
38-86	8086-8087	(	_
38-87	8087-8090	0.0	_
38-88	8090-8091	)	_
38-89	8092-8093	6	_
38-90	8094-8095	(	_
38-91	8095-8099	13.3	_
38-92	8099-8100	)	_
38-93	8105-8116	Multiracial	_
38-94	8117-8118	1	_
38-95	8119-8120	(	_
38-96	8120-8123	2.2	_
38-97	8123-8124	)	_
38-98	8125-8126	3	_
38-99	8127-8128	(	_
38-100	8128-8131	6.7	_
38-101	8131-8132	)	_
38-102	8137-8144	Unknown	_
38-103	8145-8146	3	_
38-104	8147-8148	(	_
38-105	8148-8151	6.7	_
38-106	8151-8152	)	_
38-107	8153-8154	2	_
38-108	8155-8156	(	_
38-109	8156-8159	4.4	_
38-110	8159-8160	)	_
38-111	8164-8171	Smokers	_
38-112	8172-8174	26	_
38-113	8175-8176	(	_
38-114	8176-8180	57.8	_
38-115	8180-8181	)	_
38-116	8182-8183	0	_
38-117	8184-8185	(	_
38-118	8185-8188	0.0	_
38-119	8188-8189	)	_
38-120	8190-8191	<	_
38-121	8191-8197	0.0001	_
38-122	8200-8210	Rs10514299	_
38-123	8211-8219	Genotype	_
38-124	8223-8225	CC	_
38-125	8226-8228	35	_
38-126	8229-8231	33	_
38-127	8232-8237	0.624	_
38-128	8241-8243	CT	_
38-129	8243-8244	/	_
38-130	8244-8246	TT	_
38-131	8247-8249	10	_
38-132	8250-8252	12	_
38-133	8256-8263	Alcohol	_
38-134	8264-8274	dependence	_
38-135	8275-8283	severity	_
38-136	8284-8289	score	_
38-137	8289-8290	,	_
38-138	8291-8295	mean	_
38-139	8296-8297	(	_
38-140	8297-8299	SD	_
38-141	8299-8300	)	_
38-142	8301-8306	19.68	_
38-143	8307-8308	(	_
38-144	8308-8312	7.70	_
38-145	8312-8313	)	_
38-146	8314-8315	(	_
38-147	8315-8316	N	_
38-148	8317-8318	=	_
38-149	8319-8321	38	_
38-150	8321-8322	)	_
38-151	8323-8327	1.13	_
38-152	8328-8329	(	_
38-153	8329-8333	2.25	_
38-154	8333-8334	)	_
38-155	8335-8336	(	_
38-156	8336-8337	N	_
38-157	8338-8339	=	_
38-158	8340-8342	31	_
38-159	8342-8343	)	_
38-160	8344-8345	<	_
38-161	8345-8351	0.0001	_
38-162	8354-8361	Average	_
38-163	8362-8368	number	_
38-164	8369-8371	of	_
38-165	8372-8380	drinking	_
38-166	8381-8385	days	_
38-167	8386-8388	in	_
38-168	8389-8393	past	_
38-169	8394-8396	90	_
38-170	8397-8401	days	_
38-171	8401-8402	,	_
38-172	8403-8407	mean	_
38-173	8408-8409	(	_
38-174	8409-8411	SD	_
38-175	8411-8412	)	_
38-176	8413-8418	69.60	_
38-177	8419-8420	(	_
38-178	8420-8425	25.19	_
38-179	8425-8426	)	_
38-180	8427-8432	18.76	_
38-181	8433-8434	(	_
38-182	8434-8439	16.08	_
38-183	8439-8440	)	_
38-184	8441-8442	<	_
38-185	8442-8448	0.0001	_
38-186	8451-8457	Number	_
38-187	8458-8460	of	_
38-188	8461-8466	heavy	_
38-189	8467-8475	drinking	_
38-190	8476-8480	days	_
38-191	8481-8483	in	_
38-192	8484-8488	past	_
38-193	8489-8491	90	_
38-194	8492-8496	days	_
38-195	8496-8497	,	_
38-196	8498-8502	mean	_
38-197	8503-8504	(	_
38-198	8504-8506	SD	_
38-199	8506-8507	)	_
38-200	8508-8513	59.49	_
38-201	8514-8515	(	_
38-202	8515-8520	30.65	_
38-203	8520-8521	)	_
38-204	8522-8526	2.42	_
38-205	8527-8528	(	_
38-206	8528-8532	7.19	_
38-207	8532-8533	)	_
38-208	8534-8535	<	_
38-209	8535-8541	0.0001	_
38-210	8544-8551	Average	_
38-211	8552-8558	number	_
38-212	8559-8561	of	_
38-213	8562-8568	drinks	_
38-214	8569-8572	per	_
38-215	8573-8581	drinking	_
38-216	8582-8585	day	_
38-217	8585-8586	,	_
38-218	8587-8591	mean	_
38-219	8592-8593	(	_
38-220	8593-8595	SD	_
38-221	8595-8596	)	_
38-222	8597-8602	13.11	_
38-223	8603-8604	(	_
38-224	8604-8608	8.84	_
38-225	8608-8609	)	_
38-226	8610-8614	1.80	_
38-227	8615-8616	(	_
38-228	8616-8620	1.78	_
38-229	8620-8621	)	_
38-230	8622-8623	<	_
38-231	8623-8629	0.0001	_
38-232	8632-8637	MADRS	_
38-233	8638-8643	Score	_
38-234	8643-8644	,	_
38-235	8645-8649	mean	_
38-236	8650-8651	(	_
38-237	8651-8653	SD	_
38-238	8653-8654	)	_
38-239	8655-8660	12.13	_
38-240	8661-8662	(	_
38-241	8662-8667	10.21	_
38-242	8667-8668	)	_
38-243	8669-8673	0.87	_
38-244	8674-8675	(	_
38-245	8675-8679	1.67	_
38-246	8679-8680	)	_
38-247	8681-8682	<	_
38-248	8682-8688	0.0001	_
38-249	8691-8694	Any	_
38-250	8695-8702	anxiety	_
38-251	8703-8719	disorder—current	_
38-252	8720-8721	8	_
38-253	8722-8723	(	_
38-254	8723-8726	9.0	_
38-255	8726-8727	)	_
38-256	8728-8729	1	_
38-257	8730-8731	(	_
38-258	8731-8734	1.1	_
38-259	8734-8735	)	_
38-260	8736-8741	0.010	_
38-261	8744-8747	Any	_
38-262	8748-8755	anxiety	_
38-263	8756-8773	disorder—lifetime	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-264	8774-8776	11	_
38-265	8777-8778	(	_
38-266	8778-8782	12.4	_
38-267	8782-8783	)	_
38-268	8784-8785	1	_
38-269	8786-8787	(	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-270	8787-8790	1.1	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-271	8790-8791	)	_
38-272	8792-8797	0.002	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-273	8800-8811	Generalized	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-274	8812-8819	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-275	8820-8836	disorder—current	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-276	8837-8838	3	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-277	8839-8840	(	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-278	8840-8843	3.4	_
38-279	8843-8844	)	_
38-280	8845-8846	1	_
38-281	8847-8848	(	_
38-282	8848-8851	1.1	_
38-283	8851-8852	)	_
38-284	8853-8858	0.030	_
38-285	8861-8872	Generalized	_
38-286	8873-8880	anxiety	_
38-287	8881-8898	disorder—lifetime	_
38-288	8899-8900	3	_
38-289	8901-8902	(	_
38-290	8902-8905	3.4	_
38-291	8905-8906	)	_
38-292	8907-8908	1	_
38-293	8909-8910	(	_
38-294	8910-8913	1.1	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-295	8913-8914	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-296	8915-8920	0.030	_
38-297	8923-8936	Posttraumatic	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-298	8937-8943	stress	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-299	8944-8960	disorder—current	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-300	8961-8962	2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-301	8963-8964	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-302	8964-8967	2.3	_
38-303	8967-8968	)	_
38-304	8969-8970	0	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-305	8971-8972	(	_
38-306	8972-8975	0.0	_
38-307	8975-8976	)	_
38-308	8977-8982	0.150	_
38-309	8985-8998	Posttraumatic	_
38-310	8999-9005	stress	_
38-311	9006-9023	disorder—lifetime	_
38-312	9024-9025	2	_
38-313	9026-9027	(	_
38-314	9027-9030	2.3	_
38-315	9030-9031	)	_
38-316	9032-9033	0	_
38-317	9034-9035	(	_
38-318	9035-9038	0.0	_
38-319	9038-9039	)	_
38-320	9040-9045	0.150	_
38-321	9048-9051	Any	_
38-322	9052-9056	mood	_
38-323	9057-9073	disorder—current	_
38-324	9074-9075	5	_
38-325	9076-9077	(	_
38-326	9077-9080	5.6	_
38-327	9080-9081	)	_
38-328	9082-9083	0	_
38-329	9084-9085	(	_
38-330	9085-9088	0.0	_
38-331	9088-9089	)	_
38-332	9090-9095	0.020	_
38-333	9098-9101	Any	_
38-334	9102-9106	mood	_
38-335	9107-9124	disorder—lifetime	_
38-336	9125-9127	10	_
38-337	9128-9129	(	_
38-338	9129-9133	11.2	_
38-339	9133-9134	)	_
38-340	9135-9136	8	_
38-341	9137-9138	(	_
38-342	9138-9141	9.0	_
38-343	9141-9142	)	_
38-344	9143-9148	0.560	_
38-345	9151-9156	Major	_
38-346	9157-9167	depressive	_
38-347	9168-9184	disorder—current	_
38-348	9185-9186	3	_
38-349	9187-9188	(	_
38-350	9188-9191	3.4	_
38-351	9191-9192	)	_
38-352	9193-9194	0	_
38-353	9195-9196	(	_
38-354	9196-9199	0.0	_
38-355	9199-9200	)	_
38-356	9201-9206	0.070	_
38-357	9209-9214	Major	_
38-358	9215-9225	depressive	_
38-359	9226-9243	disorder—lifetime	_
38-360	9244-9245	9	_
38-361	9246-9247	(	_
38-362	9247-9251	10.1	_
38-363	9251-9252	)	_
38-364	9253-9254	8	_
38-365	9255-9256	(	_
38-366	9256-9259	9.0	_
38-367	9259-9260	)	_
38-368	9261-9266	0.750	_
38-369	9270-9274	Note	_
38-370	9274-9275	.	_

Text=Boldface indicates a significant between-group difference.
39-1	9276-9284	Boldface	_
39-2	9285-9294	indicates	_
39-3	9295-9296	a	_
39-4	9297-9308	significant	_
39-5	9309-9322	between-group	_
39-6	9323-9333	difference	_
39-7	9333-9334	.	_

Text=Numbers reported are N (%), unless stated otherwise.
40-1	9335-9342	Numbers	_
40-2	9343-9351	reported	_
40-3	9352-9355	are	_
40-4	9356-9357	N	_
40-5	9358-9359	(	_
40-6	9359-9360	%	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-7	9360-9361	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-8	9361-9362	,	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-9	9363-9369	unless	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-10	9370-9376	stated	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-11	9377-9386	otherwise	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-12	9386-9387	.	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging

Text=Ethnicity reported in this table was based on self-report.
41-1	9388-9397	Ethnicity	_
41-2	9398-9406	reported	_
41-3	9407-9409	in	_
41-4	9410-9414	this	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
41-5	9415-9420	table	_
41-6	9421-9424	was	_
41-7	9425-9430	based	_
41-8	9431-9433	on	_
41-9	9434-9445	self-report	_
41-10	9445-9446	.	_

Text=Diagnoses are based on DSM-IV-TR and were assessed with the SCID-IV MADRS Montgomery-Asberg Depression Rating Scale The Neuroimaging Sample included 90 participants (45 AD and 45 HC) with a mean age of 39.78 (SD = 11.33; see Table 1).
42-1	9447-9456	Diagnoses	_
42-2	9457-9460	are	_
42-3	9461-9466	based	_
42-4	9467-9469	on	_
42-5	9470-9479	DSM-IV-TR	_
42-6	9480-9483	and	_
42-7	9484-9488	were	_
42-8	9489-9497	assessed	_
42-9	9498-9502	with	_
42-10	9503-9506	the	_
42-11	9507-9514	SCID-IV	_
42-12	9515-9520	MADRS	_
42-13	9521-9538	Montgomery-Asberg	_
42-14	9539-9549	Depression	_
42-15	9550-9556	Rating	_
42-16	9557-9562	Scale	_
42-17	9563-9566	The	_
42-18	9567-9579	Neuroimaging	_
42-19	9580-9586	Sample	_
42-20	9587-9595	included	_
42-21	9596-9598	90	_
42-22	9599-9611	participants	_
42-23	9612-9613	(	_
42-24	9613-9615	45	_
42-25	9616-9618	AD	_
42-26	9619-9622	and	_
42-27	9623-9625	45	_
42-28	9626-9628	HC	_
42-29	9628-9629	)	_
42-30	9630-9634	with	_
42-31	9635-9636	a	_
42-32	9637-9641	mean	_
42-33	9642-9645	age	_
42-34	9646-9648	of	_
42-35	9649-9654	39.78	_
42-36	9655-9656	(	_
42-37	9656-9658	SD	_
42-38	9659-9660	=	_
42-39	9661-9666	11.33	_
42-40	9666-9667	;	_
42-41	9668-9671	see	_
42-42	9672-9677	Table	_
42-43	9678-9679	1	_
42-44	9679-9680	)	_
42-45	9680-9681	.	_

Text=Prior to study participation, participants in the Neuroimaging and NIAAA Sample provided informed written consent in accordance with the Declaration of Helsinki and as approved by the National Institute on Alcohol Abuse and Alcoholism Review Board.
43-1	9682-9687	Prior	_
43-2	9688-9690	to	_
43-3	9691-9696	study	_
43-4	9697-9710	participation	_
43-5	9710-9711	,	_
43-6	9712-9724	participants	_
43-7	9725-9727	in	_
43-8	9728-9731	the	_
43-9	9732-9744	Neuroimaging	_
43-10	9745-9748	and	_
43-11	9749-9754	NIAAA	_
43-12	9755-9761	Sample	_
43-13	9762-9770	provided	_
43-14	9771-9779	informed	_
43-15	9780-9787	written	_
43-16	9788-9795	consent	_
43-17	9796-9798	in	_
43-18	9799-9809	accordance	_
43-19	9810-9814	with	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-20	9815-9818	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-21	9819-9830	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-22	9831-9833	of	_
43-23	9834-9842	Helsinki	_
43-24	9843-9846	and	_
43-25	9847-9849	as	_
43-26	9850-9858	approved	_
43-27	9859-9861	by	_
43-28	9862-9865	the	_
43-29	9866-9874	National	_
43-30	9875-9884	Institute	_
43-31	9885-9887	on	_
43-32	9888-9895	Alcohol	_
43-33	9896-9901	Abuse	_
43-34	9902-9905	and	_
43-35	9906-9916	Alcoholism	_
43-36	9917-9923	Review	_
43-37	9924-9929	Board	_
43-38	9929-9930	.	_

Text=All participants completed the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-IV).
44-1	9931-9934	All	_
44-2	9935-9947	participants	_
44-3	9948-9957	completed	_
44-4	9958-9961	the	_
44-5	9962-9972	Structured	_
44-6	9973-9981	Clinical	_
44-7	9982-9991	Interview	_
44-8	9992-9995	for	_
44-9	9996-10005	DSM-IV-TR	_
44-10	10006-10010	Axis	_
44-11	10011-10012	I	_
44-12	10013-10022	Disorders	_
44-13	10023-10024	(	_
44-14	10024-10031	SCID-IV	_
44-15	10031-10032	)	_
44-16	10032-10033	.	_

Text=Given that DSM - 5 criteria for alcohol use disorder are less stringent compared to DSM-IV criteria for AD, all individuals likely fall into the moderate / severe alcohol use disorder categories in DSM - 5.
45-1	10034-10039	Given	_
45-2	10040-10044	that	_
45-3	10045-10048	DSM	_
45-4	10048-10049	-	_
45-5	10049-10050	5	_
45-6	10051-10059	criteria	_
45-7	10060-10063	for	_
45-8	10064-10071	alcohol	_
45-9	10072-10075	use	_
45-10	10076-10084	disorder	_
45-11	10085-10088	are	_
45-12	10089-10093	less	_
45-13	10094-10103	stringent	_
45-14	10104-10112	compared	_
45-15	10113-10115	to	_
45-16	10116-10122	DSM-IV	_
45-17	10123-10131	criteria	_
45-18	10132-10135	for	_
45-19	10136-10138	AD	_
45-20	10138-10139	,	_
45-21	10140-10143	all	_
45-22	10144-10155	individuals	_
45-23	10156-10162	likely	_
45-24	10163-10167	fall	_
45-25	10168-10172	into	_
45-26	10173-10176	the	_
45-27	10177-10185	moderate	_
45-28	10185-10186	/	_
45-29	10186-10192	severe	_
45-30	10193-10200	alcohol	_
45-31	10201-10204	use	_
45-32	10205-10213	disorder	_
45-33	10214-10224	categories	_
45-34	10225-10227	in	_
45-35	10228-10231	DSM	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
45-36	10231-10232	-	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
45-37	10232-10233	5	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
45-38	10233-10234	.	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol

Text=Exclusion criteria included left-handedness, contraindications for MRI (e.g., claustrophobia or pregnancy), and the presence of any significant medical or neurological diagnoses as assessed by a history and physical exam.
46-1	10235-10244	Exclusion	_
46-2	10245-10253	criteria	_
46-3	10254-10262	included	_
46-4	10263-10278	left-handedness	_
46-5	10278-10279	,	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
46-6	10280-10297	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
46-7	10298-10301	for	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
46-8	10302-10305	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
46-9	10306-10307	(	_
46-10	10307-10310	e.g	_
46-11	10310-10311	.	_
46-12	10311-10312	,	_
46-13	10313-10327	claustrophobia	_
46-14	10328-10330	or	_
46-15	10331-10340	pregnancy	_
46-16	10340-10341	)	_
46-17	10341-10342	,	_
46-18	10343-10346	and	_
46-19	10347-10350	the	_
46-20	10351-10359	presence	_
46-21	10360-10362	of	_
46-22	10363-10366	any	_
46-23	10367-10378	significant	_
46-24	10379-10386	medical	_
46-25	10387-10389	or	_
46-26	10390-10402	neurological	_
46-27	10403-10412	diagnoses	_
46-28	10413-10415	as	_
46-29	10416-10424	assessed	_
46-30	10425-10427	by	_
46-31	10428-10429	a	_
46-32	10430-10437	history	_
46-33	10438-10441	and	_
46-34	10442-10450	physical	_
46-35	10451-10455	exam	_
46-36	10455-10456	.	_

Text=Additional exclusion criteria for the HC group included DSM-IV-TR diagnoses of current / past AD, positive urine drug screens, and alcohol breathalyzer readings above zero.
47-1	10457-10467	Additional	_
47-2	10468-10477	exclusion	_
47-3	10478-10486	criteria	_
47-4	10487-10490	for	_
47-5	10491-10494	the	_
47-6	10495-10497	HC	_
47-7	10498-10503	group	_
47-8	10504-10512	included	_
47-9	10513-10522	DSM-IV-TR	_
47-10	10523-10532	diagnoses	_
47-11	10533-10535	of	_
47-12	10536-10543	current	_
47-13	10543-10544	/	_
47-14	10544-10548	past	_
47-15	10549-10551	AD	_
47-16	10551-10552	,	_
47-17	10553-10561	positive	_
47-18	10562-10567	urine	_
47-19	10568-10572	drug	_
47-20	10573-10580	screens	_
47-21	10580-10581	,	_
47-22	10582-10585	and	_
47-23	10586-10593	alcohol	_
47-24	10594-10606	breathalyzer	_
47-25	10607-10615	readings	_
47-26	10616-10621	above	_
47-27	10622-10626	zero	_
47-28	10626-10627	.	_

Text=FMRI scans were obtained while participants completed a modified version of the MID task where approximately 70% of trials were successful.
48-1	10628-10632	FMRI	_
48-2	10633-10638	scans	_
48-3	10639-10643	were	_
48-4	10644-10652	obtained	_
48-5	10653-10658	while	_
48-6	10659-10671	participants	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
48-7	10672-10681	completed	_
48-8	10682-10683	a	_
48-9	10684-10692	modified	_
48-10	10693-10700	version	_
48-11	10701-10703	of	_
48-12	10704-10707	the	_
48-13	10708-10711	MID	_
48-14	10712-10716	task	_
48-15	10717-10722	where	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
48-16	10723-10736	approximately	_
48-17	10737-10740	70%	_
48-18	10741-10743	of	_
48-19	10744-10750	trials	_
48-20	10751-10755	were	_
48-21	10756-10766	successful	_
48-22	10766-10767	.	_

Text=Participants were not on any psychotropic medications on the day of the scan and there were no alcohol abstainers among the HC group.
49-1	10768-10780	Participants	_
49-2	10781-10785	were	_
49-3	10786-10789	not	_
49-4	10790-10792	on	_
49-5	10793-10796	any	_
49-6	10797-10809	psychotropic	_
49-7	10810-10821	medications	_
49-8	10822-10824	on	_
49-9	10825-10828	the	_
49-10	10829-10832	day	_
49-11	10833-10835	of	_
49-12	10836-10839	the	_
49-13	10840-10844	scan	_
49-14	10845-10848	and	_
49-15	10849-10854	there	_
49-16	10855-10859	were	_
49-17	10860-10862	no	_
49-18	10863-10870	alcohol	_
49-19	10871-10881	abstainers	_
49-20	10882-10887	among	_
49-21	10888-10891	the	_
49-22	10892-10894	HC	_
49-23	10895-10900	group	_
49-24	10900-10901	.	_

Text=DNA samples were obtained from all participants for genotyping.
50-1	10902-10905	DNA	_
50-2	10906-10913	samples	_
50-3	10914-10918	were	_
50-4	10919-10927	obtained	_
50-5	10928-10932	from	_
50-6	10933-10936	all	_
50-7	10937-10949	participants	_
50-8	10950-10953	for	_
50-9	10954-10964	genotyping	_
50-10	10964-10965	.	_

Text=Demographics and characteristics of the NIAAA Sample and the Lifetime Alcohol Dependence Sample NIAAA Sample N = 1858 NIAAA subsample with lifetime AD Cases N = 1123 Controls N = 735 N = 955 Gender, N, (%) Male 323 (28.8) 325 (44.2) 669 (70.0) Female 800 (71.2) 410 (55.8) 286 (30.0) Age, mean years (SD) 42.6 (10.9) 32.8 (11.6) 42.8 (10.8) Ethnicity, N, (%) Black / African American 507 (45.2) 232 (31.6) 439 (46.0) European American 531 (47.3) 411 (55.9) 441 (46.1) Asian 16 (1.4) 47 (6.4) 12 (1.3) Multiracial 21 (1.9) 20 (2.7) 18 (1.9) Native American or Alaska Native 5 (0.5) 2 (0.3) 5 (0.5) Native Hawaiian or other Pacific Islander 1 (0.1) 1 (0.1) 1 (0.1) Unknown 42 (3.7) 22 (3.0) 39 (4.1) Smokers, N, (%) 662 (59.0) 44 (6.1) 595 (62.3) MADRS score, mean (SD) 13.2 (9.8) 1.3 (3.2) 13.2 (9.8) Major depressive disorder—current, N, (%) 108 (5.8) 8 (0.4) 103 (10.8) Major depressive disorder—lifetime, N, (%) 216 (11.6) 49 (2.6) 196 (20.5) Note.
51-1	10966-10978	Demographics	_
51-2	10979-10982	and	_
51-3	10983-10998	characteristics	_
51-4	10999-11001	of	_
51-5	11002-11005	the	_
51-6	11006-11011	NIAAA	_
51-7	11012-11018	Sample	_
51-8	11019-11022	and	_
51-9	11023-11026	the	_
51-10	11027-11035	Lifetime	_
51-11	11036-11043	Alcohol	_
51-12	11044-11054	Dependence	_
51-13	11055-11061	Sample	_
51-14	11063-11068	NIAAA	_
51-15	11069-11075	Sample	_
51-16	11076-11077	N	_
51-17	11078-11079	=	_
51-18	11080-11084	1858	_
51-19	11085-11090	NIAAA	_
51-20	11091-11100	subsample	_
51-21	11101-11105	with	_
51-22	11106-11114	lifetime	_
51-23	11115-11117	AD	_
51-24	11121-11126	Cases	_
51-25	11127-11128	N	_
51-26	11129-11130	=	_
51-27	11131-11135	1123	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
51-28	11136-11144	Controls	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
51-29	11145-11146	N	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
51-30	11147-11148	=	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
51-31	11149-11152	735	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
51-32	11153-11154	N	_
51-33	11155-11156	=	_
51-34	11157-11160	955	_
51-35	11163-11169	Gender	_
51-36	11169-11170	,	_
51-37	11171-11172	N	_
51-38	11172-11173	,	_
51-39	11174-11175	(	_
51-40	11175-11176	%	_
51-41	11176-11177	)	_
51-42	11181-11185	Male	_
51-43	11186-11189	323	_
51-44	11190-11191	(	_
51-45	11191-11195	28.8	_
51-46	11195-11196	)	_
51-47	11197-11200	325	_
51-48	11201-11202	(	_
51-49	11202-11206	44.2	_
51-50	11206-11207	)	_
51-51	11208-11211	669	_
51-52	11212-11213	(	_
51-53	11213-11217	70.0	_
51-54	11217-11218	)	_
51-55	11222-11228	Female	_
51-56	11229-11232	800	_
51-57	11233-11234	(	_
51-58	11234-11238	71.2	_
51-59	11238-11239	)	_
51-60	11240-11243	410	_
51-61	11244-11245	(	_
51-62	11245-11249	55.8	_
51-63	11249-11250	)	_
51-64	11251-11254	286	_
51-65	11255-11256	(	_
51-66	11256-11260	30.0	_
51-67	11260-11261	)	_
51-68	11264-11267	Age	_
51-69	11267-11268	,	_
51-70	11269-11273	mean	_
51-71	11274-11279	years	_
51-72	11280-11281	(	_
51-73	11281-11283	SD	_
51-74	11283-11284	)	_
51-75	11285-11289	42.6	_
51-76	11290-11291	(	_
51-77	11291-11295	10.9	_
51-78	11295-11296	)	_
51-79	11297-11301	32.8	_
51-80	11302-11303	(	_
51-81	11303-11307	11.6	_
51-82	11307-11308	)	_
51-83	11309-11313	42.8	_
51-84	11314-11315	(	_
51-85	11315-11319	10.8	_
51-86	11319-11320	)	_
51-87	11323-11332	Ethnicity	_
51-88	11332-11333	,	_
51-89	11334-11335	N	_
51-90	11335-11336	,	_
51-91	11337-11338	(	_
51-92	11338-11339	%	_
51-93	11339-11340	)	_
51-94	11344-11349	Black	_
51-95	11349-11350	/	_
51-96	11350-11357	African	_
51-97	11358-11366	American	_
51-98	11367-11370	507	_
51-99	11371-11372	(	_
51-100	11372-11376	45.2	_
51-101	11376-11377	)	_
51-102	11378-11381	232	_
51-103	11382-11383	(	_
51-104	11383-11387	31.6	_
51-105	11387-11388	)	_
51-106	11389-11392	439	_
51-107	11393-11394	(	_
51-108	11394-11398	46.0	_
51-109	11398-11399	)	_
51-110	11403-11411	European	_
51-111	11412-11420	American	_
51-112	11421-11424	531	_
51-113	11425-11426	(	_
51-114	11426-11430	47.3	_
51-115	11430-11431	)	_
51-116	11432-11435	411	_
51-117	11436-11437	(	_
51-118	11437-11441	55.9	_
51-119	11441-11442	)	_
51-120	11443-11446	441	_
51-121	11447-11448	(	_
51-122	11448-11452	46.1	_
51-123	11452-11453	)	_
51-124	11457-11462	Asian	_
51-125	11463-11465	16	_
51-126	11466-11467	(	_
51-127	11467-11470	1.4	_
51-128	11470-11471	)	_
51-129	11472-11474	47	_
51-130	11475-11476	(	_
51-131	11476-11479	6.4	_
51-132	11479-11480	)	_
51-133	11481-11483	12	_
51-134	11484-11485	(	_
51-135	11485-11488	1.3	_
51-136	11488-11489	)	_
51-137	11493-11504	Multiracial	_
51-138	11505-11507	21	_
51-139	11508-11509	(	_
51-140	11509-11512	1.9	_
51-141	11512-11513	)	_
51-142	11514-11516	20	_
51-143	11517-11518	(	_
51-144	11518-11521	2.7	_
51-145	11521-11522	)	_
51-146	11523-11525	18	_
51-147	11526-11527	(	_
51-148	11527-11530	1.9	_
51-149	11530-11531	)	_
51-150	11535-11541	Native	_
51-151	11542-11550	American	_
51-152	11551-11553	or	_
51-153	11554-11560	Alaska	_
51-154	11561-11567	Native	_
51-155	11568-11569	5	_
51-156	11570-11571	(	_
51-157	11571-11574	0.5	_
51-158	11574-11575	)	_
51-159	11576-11577	2	_
51-160	11578-11579	(	_
51-161	11579-11582	0.3	_
51-162	11582-11583	)	_
51-163	11584-11585	5	_
51-164	11586-11587	(	_
51-165	11587-11590	0.5	_
51-166	11590-11591	)	_
51-167	11595-11601	Native	_
51-168	11602-11610	Hawaiian	_
51-169	11611-11613	or	_
51-170	11614-11619	other	_
51-171	11620-11627	Pacific	_
51-172	11628-11636	Islander	_
51-173	11637-11638	1	_
51-174	11639-11640	(	_
51-175	11640-11643	0.1	_
51-176	11643-11644	)	_
51-177	11645-11646	1	_
51-178	11647-11648	(	_
51-179	11648-11651	0.1	_
51-180	11651-11652	)	_
51-181	11653-11654	1	_
51-182	11655-11656	(	_
51-183	11656-11659	0.1	_
51-184	11659-11660	)	_
51-185	11664-11671	Unknown	_
51-186	11672-11674	42	_
51-187	11675-11676	(	_
51-188	11676-11679	3.7	_
51-189	11679-11680	)	_
51-190	11681-11683	22	_
51-191	11684-11685	(	_
51-192	11685-11688	3.0	_
51-193	11688-11689	)	_
51-194	11690-11692	39	_
51-195	11693-11694	(	_
51-196	11694-11697	4.1	_
51-197	11697-11698	)	_
51-198	11701-11708	Smokers	_
51-199	11708-11709	,	_
51-200	11710-11711	N	_
51-201	11711-11712	,	_
51-202	11713-11714	(	_
51-203	11714-11715	%	_
51-204	11715-11716	)	_
51-205	11717-11720	662	_
51-206	11721-11722	(	_
51-207	11722-11726	59.0	_
51-208	11726-11727	)	_
51-209	11728-11730	44	_
51-210	11731-11732	(	_
51-211	11732-11735	6.1	_
51-212	11735-11736	)	_
51-213	11737-11740	595	_
51-214	11741-11742	(	_
51-215	11742-11746	62.3	_
51-216	11746-11747	)	_
51-217	11750-11755	MADRS	_
51-218	11756-11761	score	_
51-219	11761-11762	,	_
51-220	11763-11767	mean	_
51-221	11768-11769	(	_
51-222	11769-11771	SD	_
51-223	11771-11772	)	_
51-224	11773-11777	13.2	_
51-225	11778-11779	(	_
51-226	11779-11782	9.8	_
51-227	11782-11783	)	_
51-228	11784-11787	1.3	_
51-229	11788-11789	(	_
51-230	11789-11792	3.2	_
51-231	11792-11793	)	_
51-232	11794-11798	13.2	_
51-233	11799-11800	(	_
51-234	11800-11803	9.8	_
51-235	11803-11804	)	_
51-236	11807-11812	Major	_
51-237	11813-11823	depressive	_
51-238	11824-11840	disorder—current	_
51-239	11840-11841	,	_
51-240	11842-11843	N	_
51-241	11843-11844	,	_
51-242	11845-11846	(	_
51-243	11846-11847	%	_
51-244	11847-11848	)	_
51-245	11849-11852	108	_
51-246	11853-11854	(	_
51-247	11854-11857	5.8	_
51-248	11857-11858	)	_
51-249	11859-11860	8	_
51-250	11861-11862	(	_
51-251	11862-11865	0.4	_
51-252	11865-11866	)	_
51-253	11867-11870	103	_
51-254	11871-11872	(	_
51-255	11872-11876	10.8	_
51-256	11876-11877	)	_
51-257	11880-11885	Major	_
51-258	11886-11896	depressive	_
51-259	11897-11914	disorder—lifetime	_
51-260	11914-11915	,	_
51-261	11916-11917	N	_
51-262	11917-11918	,	_
51-263	11919-11920	(	_
51-264	11920-11921	%	_
51-265	11921-11922	)	_
51-266	11923-11926	216	_
51-267	11927-11928	(	_
51-268	11928-11932	11.6	_
51-269	11932-11933	)	_
51-270	11934-11936	49	_
51-271	11937-11938	(	_
51-272	11938-11941	2.6	_
51-273	11941-11942	)	_
51-274	11943-11946	196	_
51-275	11947-11948	(	_
51-276	11948-11952	20.5	_
51-277	11952-11953	)	_
51-278	11957-11961	Note	_
51-279	11961-11962	.	_

Text=Ethnicity reported in this table was based on self-report MADRS Montgomery-Asberg Depression Rating Scale The NIAAA Sample consisted of 1123 individuals with a DSM-IV-TR diagnosis of AD and 735 HCs who enrolled in research studies at the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health Clinical Center in Bethesda, MD (see Table 2). 531 individuals with AD and 411 controls were of European American (EA) descent.
52-1	11963-11972	Ethnicity	_
52-2	11973-11981	reported	_
52-3	11982-11984	in	_
52-4	11985-11989	this	_
52-5	11990-11995	table	_
52-6	11996-11999	was	_
52-7	12000-12005	based	_
52-8	12006-12008	on	_
52-9	12009-12020	self-report	_
52-10	12021-12026	MADRS	_
52-11	12027-12044	Montgomery-Asberg	_
52-12	12045-12055	Depression	_
52-13	12056-12062	Rating	_
52-14	12063-12068	Scale	_
52-15	12069-12072	The	_
52-16	12073-12078	NIAAA	_
52-17	12079-12085	Sample	_
52-18	12086-12095	consisted	_
52-19	12096-12098	of	_
52-20	12099-12103	1123	_
52-21	12104-12115	individuals	_
52-22	12116-12120	with	_
52-23	12121-12122	a	_
52-24	12123-12132	DSM-IV-TR	_
52-25	12133-12142	diagnosis	_
52-26	12143-12145	of	_
52-27	12146-12148	AD	_
52-28	12149-12152	and	_
52-29	12153-12156	735	_
52-30	12157-12160	HCs	_
52-31	12161-12164	who	_
52-32	12165-12173	enrolled	_
52-33	12174-12176	in	_
52-34	12177-12185	research	_
52-35	12186-12193	studies	_
52-36	12194-12196	at	_
52-37	12197-12200	the	_
52-38	12201-12209	National	_
52-39	12210-12219	Institute	_
52-40	12220-12222	on	_
52-41	12223-12230	Alcohol	_
52-42	12231-12236	Abuse	_
52-43	12237-12240	and	_
52-44	12241-12251	Alcoholism	_
52-45	12252-12254	at	_
52-46	12255-12258	the	_
52-47	12259-12267	National	_
52-48	12268-12278	Institutes	_
52-49	12279-12281	of	_
52-50	12282-12288	Health	_
52-51	12289-12297	Clinical	_
52-52	12298-12304	Center	_
52-53	12305-12307	in	_
52-54	12308-12316	Bethesda	_
52-55	12316-12317	,	_
52-56	12318-12320	MD	_
52-57	12321-12322	(	_
52-58	12322-12325	see	_
52-59	12326-12331	Table	_
52-60	12332-12333	2	_
52-61	12333-12334	)	_
52-62	12334-12335	.	_
52-63	12336-12339	531	_
52-64	12340-12351	individuals	_
52-65	12352-12356	with	_
52-66	12357-12359	AD	_
52-67	12360-12363	and	_
52-68	12364-12367	411	_
52-69	12368-12376	controls	_
52-70	12377-12381	were	_
52-71	12382-12384	of	_
52-72	12385-12393	European	_
52-73	12394-12402	American	_
52-74	12403-12404	(	_
52-75	12404-12406	EA	_
52-76	12406-12407	)	_
52-77	12408-12415	descent	_
52-78	12415-12416	.	_

Text=A total of 507 individuals with AD and 232 controls were of African American (AA) descent.
53-1	12417-12418	A	_
53-2	12419-12424	total	_
53-3	12425-12427	of	_
53-4	12428-12431	507	_
53-5	12432-12443	individuals	_
53-6	12444-12448	with	_
53-7	12449-12451	AD	_
53-8	12452-12455	and	_
53-9	12456-12459	232	_
53-10	12460-12468	controls	_
53-11	12469-12473	were	_
53-12	12474-12476	of	_
53-13	12477-12484	African	_
53-14	12485-12493	American	_
53-15	12494-12495	(	_
53-16	12495-12497	AA	_
53-17	12497-12498	)	_
53-18	12499-12506	descent	_
53-19	12506-12507	.	_

Text=All participants provided blood samples for genotyping.
54-1	12508-12511	All	_
54-2	12512-12524	participants	_
54-3	12525-12533	provided	_
54-4	12534-12539	blood	_
54-5	12540-12547	samples	_
54-6	12548-12551	for	_
54-7	12552-12562	genotyping	_
54-8	12562-12563	.	_

Text=The SAGE was funded by the National Human Genome Research Institute as part of the Gene Environment Association Studies (GENEVA) that consisted of three major studies of addictive disorders: The Collaborative Study on the Genetics of Alcoholism (COGA), the Family Study of Cocaine Dependence (FSCD), and the Collaborative Genetic Study of Nicotine Dependence (COGEND).
55-1	12564-12567	The	_
55-2	12568-12572	SAGE	_
55-3	12573-12576	was	_
55-4	12577-12583	funded	_
55-5	12584-12586	by	_
55-6	12587-12590	the	_
55-7	12591-12599	National	_
55-8	12600-12605	Human	_
55-9	12606-12612	Genome	_
55-10	12613-12621	Research	_
55-11	12622-12631	Institute	_
55-12	12632-12634	as	_
55-13	12635-12639	part	_
55-14	12640-12642	of	_
55-15	12643-12646	the	_
55-16	12647-12651	Gene	_
55-17	12652-12663	Environment	_
55-18	12664-12675	Association	_
55-19	12676-12683	Studies	_
55-20	12684-12685	(	_
55-21	12685-12691	GENEVA	_
55-22	12691-12692	)	_
55-23	12693-12697	that	_
55-24	12698-12707	consisted	_
55-25	12708-12710	of	_
55-26	12711-12716	three	_
55-27	12717-12722	major	_
55-28	12723-12730	studies	_
55-29	12731-12733	of	_
55-30	12734-12743	addictive	_
55-31	12744-12753	disorders	_
55-32	12753-12754	:	_
55-33	12755-12758	The	_
55-34	12759-12772	Collaborative	_
55-35	12773-12778	Study	_
55-36	12779-12781	on	_
55-37	12782-12785	the	_
55-38	12786-12794	Genetics	_
55-39	12795-12797	of	_
55-40	12798-12808	Alcoholism	_
55-41	12809-12810	(	_
55-42	12810-12814	COGA	_
55-43	12814-12815	)	_
55-44	12815-12816	,	_
55-45	12817-12820	the	_
55-46	12821-12827	Family	_
55-47	12828-12833	Study	_
55-48	12834-12836	of	_
55-49	12837-12844	Cocaine	_
55-50	12845-12855	Dependence	_
55-51	12856-12857	(	_
55-52	12857-12861	FSCD	_
55-53	12861-12862	)	_
55-54	12862-12863	,	_
55-55	12864-12867	and	_
55-56	12868-12871	the	_
55-57	12872-12885	Collaborative	_
55-58	12886-12893	Genetic	_
55-59	12894-12899	Study	_
55-60	12900-12902	of	_
55-61	12903-12911	Nicotine	_
55-62	12912-12922	Dependence	_
55-63	12923-12924	(	_
55-64	12924-12930	COGEND	_
55-65	12930-12931	)	_
55-66	12931-12932	.	_

Text=The accession number of dbGaP is phs000092. v1. p1.
56-1	12933-12936	The	_
56-2	12937-12946	accession	_
56-3	12947-12953	number	_
56-4	12954-12956	of	_
56-5	12957-12962	dbGaP	_
56-6	12963-12965	is	_
56-7	12966-12975	phs000092	_
56-8	12975-12976	.	_
56-9	12976-12978	v1	_
56-10	12978-12979	.	_
56-11	12979-12981	p1	_
56-12	12981-12982	.	_

Text=The EA subgroup of the SAGE Sample consisted of 1162 cases (mean age = 38.2 (9.94); 62% male) and 1346 controls (mean age 38.6 (9.44); 30.3% male).
57-1	12983-12986	The	_
57-2	12987-12989	EA	_
57-3	12990-12998	subgroup	_
57-4	12999-13001	of	_
57-5	13002-13005	the	_
57-6	13006-13010	SAGE	_
57-7	13011-13017	Sample	_
57-8	13018-13027	consisted	_
57-9	13028-13030	of	_
57-10	13031-13035	1162	_
57-11	13036-13041	cases	_
57-12	13042-13043	(	_
57-13	13043-13047	mean	_
57-14	13048-13051	age	_
57-15	13052-13053	=	_
57-16	13054-13058	38.2	_
57-17	13059-13060	(	_
57-18	13060-13064	9.94	_
57-19	13064-13065	)	_
57-20	13065-13066	;	_
57-21	13067-13070	62%	_
57-22	13071-13075	male	_
57-23	13075-13076	)	_
57-24	13077-13080	and	_
57-25	13081-13085	1346	_
57-26	13086-13094	controls	_
57-27	13095-13096	(	_
57-28	13096-13100	mean	_
57-29	13101-13104	age	_
57-30	13105-13109	38.6	_
57-31	13110-13111	(	_
57-32	13111-13115	9.44	_
57-33	13115-13116	)	_
57-34	13116-13117	;	_
57-35	13118-13123	30.3%	_
57-36	13124-13128	male	_
57-37	13128-13129	)	_
57-38	13129-13130	.	_

Text=The AA subgroup consisted of 686 cases (mean age = 40.3 (7.7); 61% male) and 644 controls (mean age = 39.6 (7.2); 36% male).
58-1	13131-13134	The	_
58-2	13135-13137	AA	_
58-3	13138-13146	subgroup	_
58-4	13147-13156	consisted	_
58-5	13157-13159	of	_
58-6	13160-13163	686	_
58-7	13164-13169	cases	_
58-8	13170-13171	(	_
58-9	13171-13175	mean	_
58-10	13176-13179	age	_
58-11	13180-13181	=	_
58-12	13182-13186	40.3	_
58-13	13187-13188	(	_
58-14	13188-13191	7.7	_
58-15	13191-13192	)	_
58-16	13192-13193	;	_
58-17	13194-13197	61%	_
58-18	13198-13202	male	_
58-19	13202-13203	)	_
58-20	13204-13207	and	_
58-21	13208-13211	644	_
58-22	13212-13220	controls	_
58-23	13221-13222	(	_
58-24	13222-13226	mean	_
58-25	13227-13230	age	_
58-26	13231-13232	=	_
58-27	13233-13237	39.6	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
58-28	13238-13239	(	_
58-29	13239-13242	7.2	_
58-30	13242-13243	)	_
58-31	13243-13244	;	_
58-32	13245-13248	36%	_
58-33	13249-13253	male	_
58-34	13253-13254	)	_
58-35	13254-13255	.	_

Text=All cases met lifetime DSM-IV criteria for AD, and were excluded if they had schizophrenia or any other psychotic illness.
59-1	13256-13259	All	_
59-2	13260-13265	cases	_
59-3	13266-13269	met	_
59-4	13270-13278	lifetime	_
59-5	13279-13285	DSM-IV	_
59-6	13286-13294	criteria	_
59-7	13295-13298	for	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
59-8	13299-13301	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
59-9	13301-13302	,	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
59-10	13303-13306	and	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
59-11	13307-13311	were	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
59-12	13312-13320	excluded	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
59-13	13321-13323	if	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
59-14	13324-13328	they	_
59-15	13329-13332	had	_
59-16	13333-13346	schizophrenia	_
59-17	13347-13349	or	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
59-18	13350-13353	any	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
59-19	13354-13359	other	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
59-20	13360-13369	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
59-21	13370-13377	illness	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
59-22	13377-13378	.	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder

Text=Controls were defined as individuals who had been exposed to alcohol, but had not met lifetime criteria for AD or other illicit substances.
60-1	13379-13387	Controls	_
60-2	13388-13392	were	_
60-3	13393-13400	defined	_
60-4	13401-13403	as	_
60-5	13404-13415	individuals	_
60-6	13416-13419	who	_
60-7	13420-13423	had	_
60-8	13424-13428	been	_
60-9	13429-13436	exposed	_
60-10	13437-13439	to	_
60-11	13440-13447	alcohol	_
60-12	13447-13448	,	_
60-13	13449-13452	but	_
60-14	13453-13456	had	_
60-15	13457-13460	not	_
60-16	13461-13464	met	_
60-17	13465-13473	lifetime	_
60-18	13474-13482	criteria	_
60-19	13483-13486	for	_
60-20	13487-13489	AD	_
60-21	13490-13492	or	_
60-22	13493-13498	other	_
60-23	13499-13506	illicit	_
60-24	13507-13517	substances	_
60-25	13517-13518	.	_

Text=Experimental paradigm Participants completed a modified version of the MID task, which required a fast button response to a target to win or avoid losing money.
61-1	13519-13531	Experimental	_
61-2	13532-13540	paradigm	_
61-3	13541-13553	Participants	_
61-4	13554-13563	completed	_
61-5	13564-13565	a	_
61-6	13566-13574	modified	_
61-7	13575-13582	version	_
61-8	13583-13585	of	_
61-9	13586-13589	the	_
61-10	13590-13593	MID	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
61-11	13594-13598	task	_
61-12	13598-13599	,	_
61-13	13600-13605	which	_
61-14	13606-13614	required	_
61-15	13615-13616	a	_
61-16	13617-13621	fast	_
61-17	13622-13628	button	_
61-18	13629-13637	response	_
61-19	13638-13640	to	_
61-20	13641-13642	a	_
61-21	13643-13649	target	_
61-22	13650-13652	to	_
61-23	13653-13656	win	_
61-24	13657-13659	or	_
61-25	13660-13665	avoid	_
61-26	13666-13672	losing	_
61-27	13673-13678	money	_
61-28	13678-13679	.	_

Text=A trial started with a crosshair for fixation, then a 2 - second presentation of a cue (a shape indicating the type of trial: reward, loss, or neutral).
62-1	13680-13681	A	_
62-2	13682-13687	trial	_
62-3	13688-13695	started	_
62-4	13696-13700	with	_
62-5	13701-13702	a	_
62-6	13703-13712	crosshair	_
62-7	13713-13716	for	_
62-8	13717-13725	fixation	_
62-9	13725-13726	,	_
62-10	13727-13731	then	_
62-11	13732-13733	a	_
62-12	13734-13735	2	_
62-13	13735-13736	-	_
62-14	13736-13742	second	_
62-15	13743-13755	presentation	_
62-16	13756-13758	of	_
62-17	13759-13760	a	_
62-18	13761-13764	cue	_
62-19	13765-13766	(	_
62-20	13766-13767	a	_
62-21	13768-13773	shape	_
62-22	13774-13784	indicating	_
62-23	13785-13788	the	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
62-24	13789-13793	type	_
62-25	13794-13796	of	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
62-26	13797-13802	trial	_
62-27	13802-13803	:	_
62-28	13804-13810	reward	_
62-29	13810-13811	,	_
62-30	13812-13816	loss	_
62-31	13816-13817	,	_
62-32	13818-13820	or	_
62-33	13821-13828	neutral	_
62-34	13828-13829	)	_
62-35	13829-13830	.	_

Text=After a delay screen of variable duration (between 0.75 and 1.75 s) the target was presented (a white-filled square to which the participants were trained to respond to).
63-1	13831-13836	After	_
63-2	13837-13838	a	_
63-3	13839-13844	delay	_
63-4	13845-13851	screen	_
63-5	13852-13854	of	_
63-6	13855-13863	variable	_
63-7	13864-13872	duration	_
63-8	13873-13874	(	_
63-9	13874-13881	between	_
63-10	13882-13886	0.75	_
63-11	13887-13890	and	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
63-12	13891-13895	1.75	_
63-13	13896-13897	s	_
63-14	13897-13898	)	_
63-15	13899-13902	the	_
63-16	13903-13909	target	_
63-17	13910-13913	was	_
63-18	13914-13923	presented	_
63-19	13924-13925	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
63-20	13925-13926	a	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
63-21	13927-13939	white-filled	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
63-22	13940-13946	square	_
63-23	13947-13949	to	_
63-24	13950-13955	which	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
63-25	13956-13959	the	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
63-26	13960-13972	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
63-27	13973-13977	were	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
63-28	13978-13985	trained	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
63-29	13986-13988	to	_
63-30	13989-13996	respond	_
63-31	13997-13999	to	_
63-32	13999-14000	)	_
63-33	14000-14001	.	_

Text=Next, another delay screen of variable duration (between 0.75 and 3 s) was presented before the feedback screen appeared.
64-1	14002-14006	Next	_
64-2	14006-14007	,	_
64-3	14008-14015	another	_
64-4	14016-14021	delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
64-5	14022-14028	screen	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
64-6	14029-14031	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
64-7	14032-14040	variable	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
64-8	14041-14049	duration	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
64-9	14050-14051	(	_
64-10	14051-14058	between	_
64-11	14059-14063	0.75	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
64-12	14064-14067	and	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
64-13	14068-14069	3	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
64-14	14070-14071	s	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
64-15	14071-14072	)	_
64-16	14073-14076	was	_
64-17	14077-14086	presented	_
64-18	14087-14093	before	_
64-19	14094-14097	the	_
64-20	14098-14106	feedback	_
64-21	14107-14113	screen	_
64-22	14114-14122	appeared	_
64-23	14122-14123	.	_

Text=The feedback screen showed the amount that was won or lost in the previous trial, which represented if the participant had successfully pressed the button in time to win or avoid losing the target amount.
65-1	14124-14127	The	_
65-2	14128-14136	feedback	_
65-3	14137-14143	screen	_
65-4	14144-14150	showed	_
65-5	14151-14154	the	_
65-6	14155-14161	amount	_
65-7	14162-14166	that	_
65-8	14167-14170	was	_
65-9	14171-14174	won	_
65-10	14175-14177	or	_
65-11	14178-14182	lost	_
65-12	14183-14185	in	_
65-13	14186-14189	the	_
65-14	14190-14198	previous	_
65-15	14199-14204	trial	_
65-16	14204-14205	,	_
65-17	14206-14211	which	_
65-18	14212-14223	represented	_
65-19	14224-14226	if	_
65-20	14227-14230	the	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
65-21	14231-14242	participant	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
65-22	14243-14246	had	_
65-23	14247-14259	successfully	_
65-24	14260-14267	pressed	_
65-25	14268-14271	the	_
65-26	14272-14278	button	_
65-27	14279-14281	in	_
65-28	14282-14286	time	_
65-29	14287-14289	to	_
65-30	14290-14293	win	_
65-31	14294-14296	or	_
65-32	14297-14302	avoid	_
65-33	14303-14309	losing	_
65-34	14310-14313	the	_
65-35	14314-14320	target	_
65-36	14321-14327	amount	_
65-37	14327-14328	.	_

Text=The total amount of money accumulated up to that point was also presented on the feedback screen.
66-1	14329-14332	The	_
66-2	14333-14338	total	_
66-3	14339-14345	amount	_
66-4	14346-14348	of	_
66-5	14349-14354	money	_
66-6	14355-14366	accumulated	_
66-7	14367-14369	up	_
66-8	14370-14372	to	_
66-9	14373-14377	that	_
66-10	14378-14383	point	_
66-11	14384-14387	was	_
66-12	14388-14392	also	_
66-13	14393-14402	presented	_
66-14	14403-14405	on	_
66-15	14406-14409	the	_
66-16	14410-14418	feedback	_
66-17	14419-14425	screen	_
66-18	14425-14426	.	_

Text=After practicing outside of the scanner and being informed that gains / losses during the task would be reflected in their final payment, each subject completed a 12 - minute fMRI session of the MID task.
67-1	14427-14432	After	_
67-2	14433-14443	practicing	_
67-3	14444-14451	outside	_
67-4	14452-14454	of	_
67-5	14455-14458	the	_
67-6	14459-14466	scanner	_
67-7	14467-14470	and	_
67-8	14471-14476	being	_
67-9	14477-14485	informed	_
67-10	14486-14490	that	_
67-11	14491-14496	gains	_
67-12	14496-14497	/	_
67-13	14497-14503	losses	_
67-14	14504-14510	during	_
67-15	14511-14514	the	_
67-16	14515-14519	task	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
67-17	14520-14525	would	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
67-18	14526-14528	be	_
67-19	14529-14538	reflected	_
67-20	14539-14541	in	_
67-21	14542-14547	their	_
67-22	14548-14553	final	_
67-23	14554-14561	payment	_
67-24	14561-14562	,	_
67-25	14563-14567	each	_
67-26	14568-14575	subject	_
67-27	14576-14585	completed	_
67-28	14586-14587	a	_
67-29	14588-14590	12	_
67-30	14590-14591	-	_
67-31	14591-14597	minute	_
67-32	14598-14602	fMRI	_
67-33	14603-14610	session	_
67-34	14611-14613	of	_
67-35	14614-14617	the	_
67-36	14618-14621	MID	_
67-37	14622-14626	task	_
67-38	14626-14627	.	_

Text=Five different cues were presented thirty times, each representing a different trial condition; neutral (no reward / no loss), low loss, high loss, low reward, and high reward.
68-1	14628-14632	Five	_
68-2	14633-14642	different	_
68-3	14643-14647	cues	_
68-4	14648-14652	were	_
68-5	14653-14662	presented	_
68-6	14663-14669	thirty	_
68-7	14670-14675	times	_
68-8	14675-14676	,	_
68-9	14677-14681	each	_
68-10	14682-14694	representing	_
68-11	14695-14696	a	_
68-12	14697-14706	different	_
68-13	14707-14712	trial	_
68-14	14713-14722	condition	_
68-15	14722-14723	;	_
68-16	14724-14731	neutral	_
68-17	14732-14733	(	_
68-18	14733-14735	no	_
68-19	14736-14742	reward	_
68-20	14742-14743	/	_
68-21	14743-14745	no	_
68-22	14746-14750	loss	_
68-23	14750-14751	)	_
68-24	14751-14752	,	_
68-25	14753-14756	low	_
68-26	14757-14761	loss	_
68-27	14761-14762	,	_
68-28	14763-14767	high	_
68-29	14768-14772	loss	_
68-30	14772-14773	,	_
68-31	14774-14777	low	_
68-32	14778-14784	reward	_
68-33	14784-14785	,	_
68-34	14786-14789	and	_
68-35	14790-14794	high	_
68-36	14795-14801	reward	http://maven.renci.org/NeuroBridge/neurobridge#Thing
68-37	14801-14802	.	_

Text=MRI data acquisition and preprocessing A Siemens 3 T Skyra scanner was used to collect whole-brain echo-planar imaging functional (36 axial slices, 4 mm slice thickness, 64 × 64 matrix and repetition time of 2000 ms) and MPRGE structural data.
69-1	14803-14806	MRI	_
69-2	14807-14811	data	_
69-3	14812-14823	acquisition	_
69-4	14824-14827	and	_
69-5	14828-14841	preprocessing	_
69-6	14842-14843	A	_
69-7	14844-14851	Siemens	_
69-8	14852-14853	3	_
69-9	14854-14855	T	_
69-10	14856-14861	Skyra	_
69-11	14862-14869	scanner	_
69-12	14870-14873	was	_
69-13	14874-14878	used	_
69-14	14879-14881	to	_
69-15	14882-14889	collect	_
69-16	14890-14901	whole-brain	_
69-17	14902-14913	echo-planar	_
69-18	14914-14921	imaging	_
69-19	14922-14932	functional	_
69-20	14933-14934	(	_
69-21	14934-14936	36	_
69-22	14937-14942	axial	_
69-23	14943-14949	slices	_
69-24	14949-14950	,	_
69-25	14951-14952	4	_
69-26	14953-14955	mm	_
69-27	14956-14961	slice	_
69-28	14962-14971	thickness	_
69-29	14971-14972	,	_
69-30	14973-14975	64	_
69-31	14976-14977	×	_
69-32	14978-14980	64	_
69-33	14981-14987	matrix	_
69-34	14988-14991	and	_
69-35	14992-15002	repetition	_
69-36	15003-15007	time	_
69-37	15008-15010	of	_
69-38	15011-15015	2000	_
69-39	15016-15018	ms	_
69-40	15018-15019	)	_
69-41	15020-15023	and	_
69-42	15024-15029	MPRGE	_
69-43	15030-15040	structural	_
69-44	15041-15045	data	_
69-45	15045-15046	.	_

Text=Preprocessing and analysis was performed using AFNI software package.
70-1	15047-15060	Preprocessing	_
70-2	15061-15064	and	_
70-3	15065-15073	analysis	_
70-4	15074-15077	was	_
70-5	15078-15087	performed	_
70-6	15088-15093	using	_
70-7	15094-15098	AFNI	_
70-8	15099-15107	software	_
70-9	15108-15115	package	_
70-10	15115-15116	.	_

Text=Large transients removal was performed before slice-time correction, then nuisance variables were de-trended, including the six parameter estimates for head motion.
71-1	15117-15122	Large	_
71-2	15123-15133	transients	_
71-3	15134-15141	removal	_
71-4	15142-15145	was	_
71-5	15146-15155	performed	_
71-6	15156-15162	before	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
71-7	15163-15173	slice-time	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
71-8	15174-15184	correction	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
71-9	15184-15185	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
71-10	15186-15190	then	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
71-11	15191-15199	nuisance	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
71-12	15200-15209	variables	_
71-13	15210-15214	were	_
71-14	15215-15225	de-trended	_
71-15	15225-15226	,	_
71-16	15227-15236	including	_
71-17	15237-15240	the	_
71-18	15241-15244	six	_
71-19	15245-15254	parameter	_
71-20	15255-15264	estimates	_
71-21	15265-15268	for	_
71-22	15269-15273	head	_
71-23	15274-15280	motion	_
71-24	15280-15281	.	_

Text=No participants had any condition censored more than 20% (motion higher than 0.3 mm was censored out), a criterion to be excluded from the analysis.
72-1	15282-15284	No	_
72-2	15285-15297	participants	_
72-3	15298-15301	had	_
72-4	15302-15305	any	_
72-5	15306-15315	condition	_
72-6	15316-15324	censored	_
72-7	15325-15329	more	_
72-8	15330-15334	than	_
72-9	15335-15338	20%	_
72-10	15339-15340	(	_
72-11	15340-15346	motion	_
72-12	15347-15353	higher	_
72-13	15354-15358	than	_
72-14	15359-15362	0.3	_
72-15	15363-15365	mm	_
72-16	15366-15369	was	_
72-17	15370-15378	censored	_
72-18	15379-15382	out	_
72-19	15382-15383	)	_
72-20	15383-15384	,	_
72-21	15385-15386	a	_
72-22	15387-15396	criterion	_
72-23	15397-15399	to	_
72-24	15400-15402	be	_
72-25	15403-15411	excluded	_
72-26	15412-15416	from	_
72-27	15417-15420	the	_
72-28	15421-15429	analysis	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
72-29	15429-15430	.	_

Text=Images were then coregistered to the individual structural image, resampled (2 - mm isotropic), smoothed (4 - mm full-width-half-maximum Gaussian kernel), normalized by the mean signal intensity in each voxel to reflect percent signal change, and finally transformed into the standardized.
73-1	15431-15437	Images	_
73-2	15438-15442	were	_
73-3	15443-15447	then	_
73-4	15448-15460	coregistered	_
73-5	15461-15463	to	_
73-6	15464-15467	the	_
73-7	15468-15478	individual	_
73-8	15479-15489	structural	_
73-9	15490-15495	image	_
73-10	15495-15496	,	_
73-11	15497-15506	resampled	_
73-12	15507-15508	(	_
73-13	15508-15509	2	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
73-14	15509-15510	-	_
73-15	15510-15512	mm	_
73-16	15513-15522	isotropic	_
73-17	15522-15523	)	_
73-18	15523-15524	,	_
73-19	15525-15533	smoothed	_
73-20	15534-15535	(	_
73-21	15535-15536	4	_
73-22	15536-15537	-	_
73-23	15537-15539	mm	_
73-24	15540-15563	full-width-half-maximum	_
73-25	15564-15572	Gaussian	_
73-26	15573-15579	kernel	_
73-27	15579-15580	)	_
73-28	15580-15581	,	_
73-29	15582-15592	normalized	_
73-30	15593-15595	by	_
73-31	15596-15599	the	_
73-32	15600-15604	mean	_
73-33	15605-15611	signal	_
73-34	15612-15621	intensity	_
73-35	15622-15624	in	_
73-36	15625-15629	each	_
73-37	15630-15635	voxel	_
73-38	15636-15638	to	_
73-39	15639-15646	reflect	_
73-40	15647-15654	percent	_
73-41	15655-15661	signal	_
73-42	15662-15668	change	_
73-43	15668-15669	,	_
73-44	15670-15673	and	_
73-45	15674-15681	finally	_
73-46	15682-15693	transformed	_
73-47	15694-15698	into	_
73-48	15699-15702	the	_
73-49	15703-15715	standardized	_
73-50	15715-15716	.	_

Text=BOLD fMRI data and ROI analysis Single-subject level analysis was performed using AFNI.
74-1	15717-15721	BOLD	_
74-2	15722-15726	fMRI	_
74-3	15727-15731	data	_
74-4	15732-15735	and	_
74-5	15736-15739	ROI	_
74-6	15740-15748	analysis	_
74-7	15749-15763	Single-subject	_
74-8	15764-15769	level	_
74-9	15770-15778	analysis	_
74-10	15779-15782	was	_
74-11	15783-15792	performed	_
74-12	15793-15798	using	_
74-13	15799-15803	AFNI	_
74-14	15803-15804	.	_

Text=Then, using ROI masks of the bilateral caudate, putamen, and nucleus accumbens, generated with AFNI DrawDataset plugins and following previously published literature and subtracting all nuances effects (such as pre-motor activations), except reward / loss response, we computed average percent signal change (beta weights) of the following comparisons: high reward> neutral, low reward> neutral, high loss> neutral, low loss> neutral.
75-1	15805-15809	Then	_
75-2	15809-15810	,	_
75-3	15811-15816	using	_
75-4	15817-15820	ROI	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
75-5	15821-15826	masks	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
75-6	15827-15829	of	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
75-7	15830-15833	the	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
75-8	15834-15843	bilateral	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
75-9	15844-15851	caudate	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
75-10	15851-15852	,	_
75-11	15853-15860	putamen	_
75-12	15860-15861	,	_
75-13	15862-15865	and	_
75-14	15866-15873	nucleus	_
75-15	15874-15883	accumbens	_
75-16	15883-15884	,	_
75-17	15885-15894	generated	_
75-18	15895-15899	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
75-19	15900-15904	AFNI	_
75-20	15905-15916	DrawDataset	_
75-21	15917-15924	plugins	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
75-22	15925-15928	and	_
75-23	15929-15938	following	_
75-24	15939-15949	previously	_
75-25	15950-15959	published	_
75-26	15960-15970	literature	_
75-27	15971-15974	and	_
75-28	15975-15986	subtracting	_
75-29	15987-15990	all	_
75-30	15991-15998	nuances	_
75-31	15999-16006	effects	_
75-32	16007-16008	(	_
75-33	16008-16012	such	_
75-34	16013-16015	as	_
75-35	16016-16025	pre-motor	_
75-36	16026-16037	activations	_
75-37	16037-16038	)	_
75-38	16038-16039	,	_
75-39	16040-16046	except	_
75-40	16047-16053	reward	_
75-41	16053-16054	/	_
75-42	16054-16058	loss	_
75-43	16059-16067	response	_
75-44	16067-16068	,	_
75-45	16069-16071	we	_
75-46	16072-16080	computed	_
75-47	16081-16088	average	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
75-48	16089-16096	percent	_
75-49	16097-16103	signal	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
75-50	16104-16110	change	_
75-51	16111-16112	(	_
75-52	16112-16116	beta	_
75-53	16117-16124	weights	_
75-54	16124-16125	)	_
75-55	16126-16128	of	_
75-56	16129-16132	the	_
75-57	16133-16142	following	_
75-58	16143-16154	comparisons	_
75-59	16154-16155	:	_
75-60	16156-16160	high	_
75-61	16161-16167	reward	_
75-62	16168-16169	>	_
75-63	16170-16177	neutral	_
75-64	16177-16178	,	_
75-65	16179-16182	low	_
75-66	16183-16189	reward	_
75-67	16190-16191	>	_
75-68	16192-16199	neutral	_
75-69	16199-16200	,	_
75-70	16201-16205	high	_
75-71	16206-16210	loss	_
75-72	16211-16212	>	_
75-73	16213-16220	neutral	_
75-74	16220-16221	,	_
75-75	16222-16225	low	_
75-76	16226-16230	loss	_
75-77	16231-16232	>	_
75-78	16233-16240	neutral	_
75-79	16240-16241	.	_

Text=For simplification purposes, we refer to these as high reward, low reward, high loss, and low loss, respectively.
76-1	16242-16245	For	_
76-2	16246-16260	simplification	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-3	16261-16269	purposes	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-4	16269-16270	,	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-5	16271-16273	we	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-6	16274-16279	refer	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-7	16280-16282	to	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-8	16283-16288	these	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-9	16289-16291	as	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-10	16292-16296	high	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-11	16297-16303	reward	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-12	16303-16304	,	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
76-13	16305-16308	low	_
76-14	16309-16315	reward	_
76-15	16315-16316	,	_
76-16	16317-16321	high	_
76-17	16322-16326	loss	_
76-18	16326-16327	,	_
76-19	16328-16331	and	_
76-20	16332-16335	low	_
76-21	16336-16340	loss	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
76-22	16340-16341	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
76-23	16342-16354	respectively	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
76-24	16354-16355	.	_

Text=Genotyping NIAAA Sample Large-scale genotyping was performed at the NIAAA Laboratory of Neurogenetics using the Illumina OmniExpress BeadChip (Illumina, San Diego, CA).
77-1	16356-16366	Genotyping	_
77-2	16367-16372	NIAAA	_
77-3	16373-16379	Sample	_
77-4	16380-16391	Large-scale	_
77-5	16392-16402	genotyping	_
77-6	16403-16406	was	_
77-7	16407-16416	performed	_
77-8	16417-16419	at	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
77-9	16420-16423	the	_
77-10	16424-16429	NIAAA	_
77-11	16430-16440	Laboratory	_
77-12	16441-16443	of	_
77-13	16444-16457	Neurogenetics	_
77-14	16458-16463	using	_
77-15	16464-16467	the	_
77-16	16468-16476	Illumina	_
77-17	16477-16488	OmniExpress	_
77-18	16489-16497	BeadChip	_
77-19	16498-16499	(	_
77-20	16499-16507	Illumina	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
77-21	16507-16508	,	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
77-22	16509-16512	San	_
77-23	16513-16518	Diego	_
77-24	16518-16519	,	_
77-25	16520-16522	CA	_
77-26	16522-16523	)	_
77-27	16523-16524	.	_

Text=Data for the SNP rs10514299 located within the TMEM161B-AS1 gene cluster was extracted from the larger array.
78-1	16525-16529	Data	_
78-2	16530-16533	for	_
78-3	16534-16537	the	_
78-4	16538-16541	SNP	_
78-5	16542-16552	rs10514299	_
78-6	16553-16560	located	_
78-7	16561-16567	within	_
78-8	16568-16571	the	_
78-9	16572-16584	TMEM161B-AS1	_
78-10	16585-16589	gene	_
78-11	16590-16597	cluster	_
78-12	16598-16601	was	_
78-13	16602-16611	extracted	_
78-14	16612-16616	from	_
78-15	16617-16620	the	_
78-16	16621-16627	larger	_
78-17	16628-16633	array	_
78-18	16633-16634	.	_

Text=Ancestry informative markers (AIMs; n = 2500) were extracted from the Illumina array to calculate ancestral proportions for all study participants.
79-1	16635-16643	Ancestry	_
79-2	16644-16655	informative	_
79-3	16656-16663	markers	_
79-4	16664-16665	(	_
79-5	16665-16669	AIMs	_
79-6	16669-16670	;	_
79-7	16671-16672	n	_
79-8	16673-16674	=	_
79-9	16675-16679	2500	_
79-10	16679-16680	)	_
79-11	16681-16685	were	_
79-12	16686-16695	extracted	_
79-13	16696-16700	from	_
79-14	16701-16704	the	_
79-15	16705-16713	Illumina	_
79-16	16714-16719	array	_
79-17	16720-16722	to	_
79-18	16723-16732	calculate	_
79-19	16733-16742	ancestral	_
79-20	16743-16754	proportions	_
79-21	16755-16758	for	_
79-22	16759-16762	all	_
79-23	16763-16768	study	_
79-24	16769-16781	participants	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
79-25	16781-16782	.	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial

Text=Using methods described previously for an AIM panel including 186 markers, which were not available for the current data set, the ancestry assessment identified 6 ethnic factors (Africa, Europe, Asia, Far East Asia, Oceania, and Americas).
80-1	16783-16788	Using	_
80-2	16789-16796	methods	_
80-3	16797-16806	described	_
80-4	16807-16817	previously	_
80-5	16818-16821	for	_
80-6	16822-16824	an	_
80-7	16825-16828	AIM	_
80-8	16829-16834	panel	_
80-9	16835-16844	including	_
80-10	16845-16848	186	_
80-11	16849-16856	markers	_
80-12	16856-16857	,	_
80-13	16858-16863	which	_
80-14	16864-16868	were	_
80-15	16869-16872	not	_
80-16	16873-16882	available	_
80-17	16883-16886	for	_
80-18	16887-16890	the	_
80-19	16891-16898	current	_
80-20	16899-16903	data	_
80-21	16904-16907	set	_
80-22	16907-16908	,	_
80-23	16909-16912	the	_
80-24	16913-16921	ancestry	_
80-25	16922-16932	assessment	_
80-26	16933-16943	identified	_
80-27	16944-16945	6	_
80-28	16946-16952	ethnic	_
80-29	16953-16960	factors	_
80-30	16961-16962	(	_
80-31	16962-16968	Africa	_
80-32	16968-16969	,	_
80-33	16970-16976	Europe	_
80-34	16976-16977	,	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
80-35	16978-16982	Asia	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
80-36	16982-16983	,	_
80-37	16984-16987	Far	_
80-38	16988-16992	East	_
80-39	16993-16997	Asia	_
80-40	16997-16998	,	_
80-41	16999-17006	Oceania	_
80-42	17006-17007	,	_
80-43	17008-17011	and	_
80-44	17012-17020	Americas	_
80-45	17020-17021	)	_
80-46	17021-17022	.	_

Text=SAGE Sample Whole-genome genotyping was completed using the Illumina Human - 1M platform (Illumina Inc., San Diego, CA).
81-1	17023-17027	SAGE	_
81-2	17028-17034	Sample	_
81-3	17035-17047	Whole-genome	_
81-4	17048-17058	genotyping	_
81-5	17059-17062	was	_
81-6	17063-17072	completed	_
81-7	17073-17078	using	_
81-8	17079-17082	the	_
81-9	17083-17091	Illumina	_
81-10	17092-17097	Human	_
81-11	17097-17098	-	_
81-12	17098-17100	1M	_
81-13	17101-17109	platform	_
81-14	17110-17111	(	_
81-15	17111-17119	Illumina	_
81-16	17120-17123	Inc	_
81-17	17123-17124	.	_
81-18	17124-17125	,	_
81-19	17126-17129	San	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
81-20	17130-17135	Diego	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
81-21	17135-17136	,	_
81-22	17137-17139	CA	_
81-23	17139-17140	)	_
81-24	17140-17141	.	_

Text=The 190 HapMap samples (48 HapMap control samples, 55 CEU, 55 YUR, 13 CHB, and 17 JPT) were genotyped in the same platform and population stratification analyses were performed using principal component analysis.
82-1	17142-17145	The	_
82-2	17146-17149	190	_
82-3	17150-17156	HapMap	_
82-4	17157-17164	samples	_
82-5	17165-17166	(	_
82-6	17166-17168	48	_
82-7	17169-17175	HapMap	_
82-8	17176-17183	control	_
82-9	17184-17191	samples	_
82-10	17191-17192	,	_
82-11	17193-17195	55	_
82-12	17196-17199	CEU	_
82-13	17199-17200	,	_
82-14	17201-17203	55	_
82-15	17204-17207	YUR	_
82-16	17207-17208	,	_
82-17	17209-17211	13	_
82-18	17212-17215	CHB	_
82-19	17215-17216	,	_
82-20	17217-17220	and	_
82-21	17221-17223	17	_
82-22	17224-17227	JPT	_
82-23	17227-17228	)	_
82-24	17230-17234	were	_
82-25	17235-17244	genotyped	_
82-26	17245-17247	in	_
82-27	17248-17251	the	_
82-28	17252-17256	same	_
82-29	17257-17265	platform	_
82-30	17266-17269	and	_
82-31	17270-17280	population	_
82-32	17281-17295	stratification	_
82-33	17296-17304	analyses	_
82-34	17305-17309	were	_
82-35	17310-17319	performed	_
82-36	17320-17325	using	_
82-37	17326-17335	principal	_
82-38	17336-17345	component	_
82-39	17346-17354	analysis	_
82-40	17354-17355	.	_

Text=After a series of quality control procedures (p value of Hardy-Weinberg equilibrium (HWE) <10e - 5, missing rate by SNP> 2%, missing rate by individual> 2%, minor allele frequency <1%, sex inconsistency), there were 1162 case and 1346 control samples in the EA subgroup and 686 case and 644 control samples in AA subgroup.
83-1	17356-17361	After	_
83-2	17362-17363	a	_
83-3	17364-17370	series	_
83-4	17371-17373	of	_
83-5	17374-17381	quality	_
83-6	17382-17389	control	_
83-7	17390-17400	procedures	_
83-8	17401-17402	(	_
83-9	17402-17403	p	_
83-10	17404-17409	value	_
83-11	17410-17412	of	_
83-12	17413-17427	Hardy-Weinberg	_
83-13	17428-17439	equilibrium	_
83-14	17440-17441	(	_
83-15	17441-17444	HWE	_
83-16	17444-17445	)	_
83-17	17446-17447	<	_
83-18	17448-17451	10e	_
83-19	17451-17452	-	_
83-20	17452-17453	5	_
83-21	17453-17454	,	_
83-22	17455-17462	missing	_
83-23	17463-17467	rate	_
83-24	17468-17470	by	_
83-25	17471-17474	SNP	_
83-26	17475-17476	>	_
83-27	17477-17479	2%	_
83-28	17479-17480	,	_
83-29	17481-17488	missing	_
83-30	17489-17493	rate	_
83-31	17494-17496	by	_
83-32	17497-17507	individual	_
83-33	17508-17509	>	_
83-34	17510-17512	2%	_
83-35	17512-17513	,	_
83-36	17514-17519	minor	_
83-37	17520-17526	allele	_
83-38	17527-17536	frequency	_
83-39	17537-17538	<	_
83-40	17539-17541	1%	_
83-41	17541-17542	,	_
83-42	17543-17546	sex	_
83-43	17547-17560	inconsistency	_
83-44	17560-17561	)	_
83-45	17561-17562	,	_
83-46	17563-17568	there	_
83-47	17569-17573	were	_
83-48	17574-17578	1162	_
83-49	17579-17583	case	_
83-50	17584-17587	and	_
83-51	17588-17592	1346	_
83-52	17593-17600	control	_
83-53	17601-17608	samples	_
83-54	17609-17611	in	_
83-55	17612-17615	the	_
83-56	17616-17618	EA	_
83-57	17619-17627	subgroup	_
83-58	17628-17631	and	_
83-59	17632-17635	686	_
83-60	17636-17640	case	_
83-61	17641-17644	and	_
83-62	17645-17648	644	_
83-63	17649-17656	control	_
83-64	17657-17664	samples	_
83-65	17665-17667	in	_
83-66	17668-17670	AA	_
83-67	17671-17679	subgroup	_
83-68	17679-17680	.	_

Text=Two population stratification scores (PSS) calculated based on principal component analysis were used for statistical analyses.
84-1	17681-17684	Two	_
84-2	17685-17695	population	_
84-3	17696-17710	stratification	_
84-4	17711-17717	scores	_
84-5	17718-17719	(	_
84-6	17719-17722	PSS	_
84-7	17722-17723	)	_
84-8	17724-17734	calculated	_
84-9	17735-17740	based	_
84-10	17741-17743	on	_
84-11	17744-17753	principal	_
84-12	17754-17763	component	_
84-13	17764-17772	analysis	_
84-14	17773-17777	were	_
84-15	17778-17782	used	_
84-16	17783-17786	for	_
84-17	17787-17798	statistical	_
84-18	17799-17807	analyses	_
84-19	17807-17808	.	_

Text=Statistical analysis Main analyses of the Neuroimaging Sample were run using SPSS statistical software package (IBM SPSS Statistics ® 20, IBM Corp. ©, Armonk, NY).
85-1	17809-17820	Statistical	_
85-2	17821-17829	analysis	_
85-3	17830-17834	Main	_
85-4	17835-17843	analyses	_
85-5	17844-17846	of	_
85-6	17847-17850	the	_
85-7	17851-17863	Neuroimaging	_
85-8	17864-17870	Sample	_
85-9	17871-17875	were	_
85-10	17876-17879	run	_
85-11	17880-17885	using	_
85-12	17886-17890	SPSS	_
85-13	17891-17902	statistical	_
85-14	17903-17911	software	_
85-15	17912-17919	package	_
85-16	17920-17921	(	_
85-17	17921-17924	IBM	_
85-18	17925-17929	SPSS	_
85-19	17930-17940	Statistics	_
85-20	17941-17942	®	_
85-21	17943-17945	20	_
85-22	17945-17946	,	_
85-23	17947-17950	IBM	_
85-24	17951-17955	Corp	_
85-25	17955-17956	.	_
85-26	17957-17958	©	_
85-27	17958-17959	,	_
85-28	17960-17966	Armonk	_
85-29	17966-17967	,	_
85-30	17968-17970	NY	_
85-31	17970-17971	)	_
85-32	17971-17972	.	_

Text=Baseline differences in demographic variables between cases and controls were determined using t-tests for continuous and chi-square tests for categorical variables.
86-1	17973-17981	Baseline	_
86-2	17982-17993	differences	_
86-3	17994-17996	in	_
86-4	17997-18008	demographic	_
86-5	18009-18018	variables	_
86-6	18019-18026	between	_
86-7	18027-18032	cases	_
86-8	18033-18036	and	_
86-9	18037-18045	controls	_
86-10	18046-18050	were	_
86-11	18051-18061	determined	_
86-12	18062-18067	using	_
86-13	18068-18075	t-tests	_
86-14	18076-18079	for	_
86-15	18080-18090	continuous	_
86-16	18091-18094	and	_
86-17	18095-18105	chi-square	_
86-18	18106-18111	tests	_
86-19	18112-18115	for	_
86-20	18116-18127	categorical	_
86-21	18128-18137	variables	_
86-22	18137-18138	.	_

Text=Chi-square tests were performed to test the genotypic distribution of the SNP in both cases and controls.
87-1	18139-18149	Chi-square	_
87-2	18150-18155	tests	_
87-3	18156-18160	were	_
87-4	18161-18170	performed	_
87-5	18171-18173	to	_
87-6	18174-18178	test	_
87-7	18179-18182	the	_
87-8	18183-18192	genotypic	_
87-9	18193-18205	distribution	_
87-10	18206-18208	of	_
87-11	18209-18212	the	_
87-12	18213-18216	SNP	_
87-13	18217-18219	in	_
87-14	18220-18224	both	_
87-15	18225-18230	cases	_
87-16	18231-18234	and	_
87-17	18235-18243	controls	_
87-18	18243-18244	.	_

Text=The primary outcome measure was activation in the caudate, putamen, and nucleus accumbens during reward / loss anticipation as measured by BOLD fMRI.
88-1	18245-18248	The	_
88-2	18249-18256	primary	_
88-3	18257-18264	outcome	_
88-4	18265-18272	measure	_
88-5	18273-18276	was	_
88-6	18277-18287	activation	_
88-7	18288-18290	in	_
88-8	18291-18294	the	_
88-9	18295-18302	caudate	_
88-10	18302-18303	,	_
88-11	18304-18311	putamen	_
88-12	18311-18312	,	_
88-13	18313-18316	and	_
88-14	18317-18324	nucleus	_
88-15	18325-18334	accumbens	_
88-16	18335-18341	during	_
88-17	18342-18348	reward	_
88-18	18348-18349	/	_
88-19	18349-18353	loss	_
88-20	18354-18366	anticipation	_
88-21	18367-18369	as	_
88-22	18370-18378	measured	_
88-23	18379-18381	by	_
88-24	18382-18386	BOLD	_
88-25	18387-18391	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
88-26	18391-18392	.	_

Text=Shapiro-Wilk tests confirmed that all four imaging outcomes (high reward, low reward, high loss, low loss) were normally distributed (all p ≥ 0.407).
89-1	18393-18405	Shapiro-Wilk	_
89-2	18406-18411	tests	_
89-3	18412-18421	confirmed	_
89-4	18422-18426	that	_
89-5	18427-18430	all	_
89-6	18431-18435	four	_
89-7	18436-18443	imaging	_
89-8	18444-18452	outcomes	_
89-9	18453-18454	(	_
89-10	18454-18458	high	_
89-11	18459-18465	reward	_
89-12	18465-18466	,	_
89-13	18467-18470	low	_
89-14	18471-18477	reward	_
89-15	18477-18478	,	_
89-16	18479-18483	high	_
89-17	18484-18488	loss	_
89-18	18488-18489	,	_
89-19	18490-18493	low	_
89-20	18494-18498	loss	_
89-21	18498-18499	)	_
89-22	18500-18504	were	_
89-23	18505-18513	normally	_
89-24	18514-18525	distributed	_
89-25	18526-18527	(	_
89-26	18527-18530	all	_
89-27	18531-18532	p	_
89-28	18533-18534	≥	_
89-29	18535-18540	0.407	_
89-30	18540-18541	)	_
89-31	18541-18542	.	_

Text=For the main analysis of effects of diagnosis, genotype, and their interaction on BOLD responses in the caudate, putamen, and nucleus accumbens, we conducted 2 × 2 analyses of covariance (ANCOVAs) with group (AD vs.
90-1	18543-18546	For	_
90-2	18547-18550	the	_
90-3	18551-18555	main	_
90-4	18556-18564	analysis	_
90-5	18565-18567	of	_
90-6	18568-18575	effects	_
90-7	18576-18578	of	_
90-8	18579-18588	diagnosis	_
90-9	18588-18589	,	_
90-10	18590-18598	genotype	_
90-11	18598-18599	,	_
90-12	18600-18603	and	_
90-13	18604-18609	their	_
90-14	18610-18621	interaction	_
90-15	18622-18624	on	_
90-16	18625-18629	BOLD	_
90-17	18630-18639	responses	_
90-18	18640-18642	in	_
90-19	18643-18646	the	_
90-20	18647-18654	caudate	_
90-21	18654-18655	,	_
90-22	18656-18663	putamen	_
90-23	18663-18664	,	_
90-24	18665-18668	and	_
90-25	18669-18676	nucleus	_
90-26	18677-18686	accumbens	_
90-27	18686-18687	,	_
90-28	18688-18690	we	_
90-29	18691-18700	conducted	_
90-30	18701-18702	2	_
90-31	18703-18704	×	_
90-32	18705-18706	2	_
90-33	18707-18715	analyses	_
90-34	18716-18718	of	_
90-35	18719-18729	covariance	_
90-36	18730-18731	(	_
90-37	18731-18738	ANCOVAs	_
90-38	18738-18739	)	_
90-39	18740-18744	with	_
90-40	18745-18750	group	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-41	18751-18752	(	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-42	18752-18754	AD	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-43	18755-18757	vs	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-44	18757-18758	.	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale

Text=HC) T allele carrier status (CC vs.
91-1	18759-18761	HC	_
91-2	18761-18762	)	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
91-3	18763-18764	T	_
91-4	18765-18771	allele	_
91-5	18772-18779	carrier	_
91-6	18780-18786	status	_
91-7	18787-18788	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
91-8	18788-18790	CC	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
91-9	18791-18793	vs	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
91-10	18793-18794	.	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders

Text=TT / CT–assuming a dominant model) as factors and age, gender, AIM score Europe, and AIM score Africa as covariates.
92-1	18795-18797	TT	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-2	18797-18798	/	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-3	18798-18809	CT–assuming	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-4	18810-18811	a	_
92-5	18812-18820	dominant	_
92-6	18821-18826	model	http://maven.renci.org/NeuroBridge/neurobridge#Thing
92-7	18826-18827	)	_
92-8	18828-18830	as	_
92-9	18831-18838	factors	_
92-10	18839-18842	and	_
92-11	18843-18846	age	_
92-12	18846-18847	,	_
92-13	18848-18854	gender	_
92-14	18854-18855	,	_
92-15	18856-18859	AIM	_
92-16	18860-18865	score	_
92-17	18866-18872	Europe	_
92-18	18872-18873	,	_
92-19	18874-18877	and	_
92-20	18878-18881	AIM	_
92-21	18882-18887	score	_
92-22	18888-18894	Africa	_
92-23	18895-18897	as	_
92-24	18898-18908	covariates	_
92-25	18908-18909	.	_

Text=All tests were two-tailed and considered to be statistically significant at p <0.05.
93-1	18910-18913	All	_
93-2	18914-18919	tests	_
93-3	18920-18924	were	_
93-4	18925-18935	two-tailed	_
93-5	18936-18939	and	_
93-6	18940-18950	considered	_
93-7	18951-18953	to	_
93-8	18954-18956	be	_
93-9	18957-18970	statistically	_
93-10	18971-18982	significant	_
93-11	18983-18985	at	_
93-12	18986-18987	p	_
93-13	18988-18989	<	_
93-14	18990-18994	0.05	_
93-15	18994-18995	.	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse

Text=For the NIAAA Sample, minor allele frequency, HWE, and association analyses were conducted using PLINK version 1.07.
94-1	18996-18999	For	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
94-2	19000-19003	the	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
94-3	19004-19009	NIAAA	_
94-4	19010-19016	Sample	_
94-5	19016-19017	,	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
94-6	19018-19023	minor	_
94-7	19024-19030	allele	_
94-8	19031-19040	frequency	_
94-9	19040-19041	,	_
94-10	19042-19045	HWE	_
94-11	19045-19046	,	_
94-12	19047-19050	and	_
94-13	19051-19062	association	_
94-14	19063-19071	analyses	_
94-15	19072-19076	were	_
94-16	19077-19086	conducted	_
94-17	19087-19092	using	_
94-18	19093-19098	PLINK	_
94-19	19099-19106	version	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
94-20	19107-19111	1.07	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
94-21	19111-19112	.	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse

Text=Analyses were conducted first in the entire sample, and then separately for EA and AA subgroups, based on self-report.
95-1	19113-19121	Analyses	_
95-2	19122-19126	were	_
95-3	19127-19136	conducted	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
95-4	19137-19142	first	_
95-5	19143-19145	in	_
95-6	19146-19149	the	_
95-7	19150-19156	entire	_
95-8	19157-19163	sample	_
95-9	19163-19164	,	_
95-10	19165-19168	and	http://maven.renci.org/NeuroBridge/neurobridge#Thing
95-11	19169-19173	then	_
95-12	19174-19184	separately	_
95-13	19185-19188	for	_
95-14	19189-19191	EA	_
95-15	19192-19195	and	_
95-16	19196-19198	AA	_
95-17	19199-19208	subgroups	_
95-18	19208-19209	,	_
95-19	19210-19215	based	_
95-20	19216-19218	on	_
95-21	19219-19230	self-report	_
95-22	19230-19231	.	_

Text=Case-control association with lifetime AD was determined using logistic regression, while association with the MADRS scale was determined using linear regression.
96-1	19232-19244	Case-control	_
96-2	19245-19256	association	_
96-3	19257-19261	with	_
96-4	19262-19270	lifetime	_
96-5	19271-19273	AD	_
96-6	19274-19277	was	_
96-7	19278-19288	determined	_
96-8	19289-19294	using	_
96-9	19295-19303	logistic	_
96-10	19304-19314	regression	_
96-11	19314-19315	,	_
96-12	19316-19321	while	_
96-13	19322-19333	association	_
96-14	19334-19338	with	_
96-15	19339-19342	the	_
96-16	19343-19348	MADRS	_
96-17	19349-19354	scale	_
96-18	19355-19358	was	_
96-19	19359-19369	determined	_
96-20	19370-19375	using	_
96-21	19376-19382	linear	_
96-22	19383-19393	regression	_
96-23	19393-19394	.	_

Text=Both analyses used an additive model and adjusted for age, gender, and AIM scores for European and African ancestry.
97-1	19395-19399	Both	_
97-2	19400-19408	analyses	_
97-3	19409-19413	used	_
97-4	19414-19416	an	_
97-5	19417-19425	additive	_
97-6	19426-19431	model	_
97-7	19432-19435	and	_
97-8	19436-19444	adjusted	_
97-9	19445-19448	for	_
97-10	19449-19452	age	_
97-11	19452-19453	,	_
97-12	19454-19460	gender	_
97-13	19460-19461	,	_
97-14	19462-19465	and	_
97-15	19466-19469	AIM	_
97-16	19470-19476	scores	_
97-17	19477-19480	for	_
97-18	19481-19489	European	_
97-19	19490-19493	and	_
97-20	19494-19501	African	_
97-21	19502-19510	ancestry	_
97-22	19510-19511	.	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject

Text=Similarly, for the SAGE Sample, a logistic regression model controlling for age, gender, and 2 PSS for African and European ancestry was performed with the assumption of an additive model.
98-1	19512-19521	Similarly	_
98-2	19521-19522	,	_
98-3	19523-19526	for	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
98-4	19527-19530	the	_
98-5	19531-19535	SAGE	_
98-6	19536-19542	Sample	_
98-7	19542-19543	,	_
98-8	19544-19545	a	_
98-9	19546-19554	logistic	_
98-10	19555-19565	regression	_
98-11	19566-19571	model	_
98-12	19572-19583	controlling	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
98-13	19584-19587	for	_
98-14	19588-19591	age	_
98-15	19591-19592	,	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
98-16	19593-19599	gender	_
98-17	19599-19600	,	_
98-18	19601-19604	and	_
98-19	19605-19606	2	_
98-20	19607-19610	PSS	_
98-21	19611-19614	for	_
98-22	19615-19622	African	_
98-23	19623-19626	and	_
98-24	19627-19635	European	_
98-25	19636-19644	ancestry	_
98-26	19645-19648	was	_
98-27	19649-19658	performed	_
98-28	19659-19663	with	_
98-29	19664-19667	the	_
98-30	19668-19678	assumption	_
98-31	19679-19681	of	_
98-32	19682-19684	an	_
98-33	19685-19693	additive	_
98-34	19694-19699	model	_
98-35	19699-19700	.	_

Text=Analyses were performed separately in individuals of European and African ancestry.
99-1	19701-19709	Analyses	_
99-2	19710-19714	were	http://maven.renci.org/NeuroBridge/neurobridge#Age
99-3	19715-19724	performed	_
99-4	19725-19735	separately	_
99-5	19736-19738	in	_
99-6	19739-19750	individuals	_
99-7	19751-19753	of	_
99-8	19754-19762	European	_
99-9	19763-19766	and	_
99-10	19767-19774	African	_
99-11	19775-19783	ancestry	_
99-12	19783-19784	.	_

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=

